{"study_id": 102461, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were investigating the safety and activity of the combination of nab-paclitaxel and gemcitabine in pretreated soft tissue sarcoma (STS) patients, not specifically evaluating Alanine.", "results_summary": "The study reported a 2.6% incidence of grade \u22653 alanine aminotransferase increase as a treatment-related adverse event, but no specific conclusions about Alanine's effects were drawn.", "population_specificity": "Pretreated soft tissue sarcoma (STS) patients.", "effective_dosage": "Not specified for Alanine.", "study_duration": "Not specified for Alanine.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:33:56.886149+00:00"}
{"study_id": 102464, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the clinical importance of the De Ritis Ratio (aspartate transaminase/alanine transaminase) as a prognostic, diagnostic, and predictive marker in cancer.", "results_summary": "The De Ritis Ratio was found to be strongly associated with prognostic risk factors, useful for assessing therapeutic efficacy, and capable of improving diagnostics when combined with other biomarkers. It is an accessible, inexpensive, and clinically valuable marker in cancer.", "population_specificity": "Cancer patients (specific type not specified in the abstract).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:33:57.298590+00:00"}
{"study_id": 102465, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine whether orlistat treatment improves NAFLD-related factors, including liver enzymes like alanine transaminase, in adolescents with NAFLD.", "results_summary": "Orlistat significantly improved liver enzymes (alanine transaminase and aspartate transaminase), steatosis score, NAFLD activity score, weight, BMI, glucose metabolism, and lipid profiles compared to placebo over 12 weeks, but had no significant effect on triglyceride levels.", "population_specificity": "Overweight/obese adolescents with NAFLD.", "effective_dosage": "Not specified in the abstract.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:33:57.507332+00:00"}
{"study_id": 102466, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to investigate the association between liver severity indices (including alanine aminotransferase levels) and mortality in non-cirrhotic chronic liver disease patients with COVID-19.", "results_summary": "Higher alanine aminotransferase levels were observed in non-survivors, but the study did not focus on alanine's efficacy or safety as a supplement. The primary findings related to liver severity indices (ALBI grade, FIB-4 index) and their correlation with mortality.", "population_specificity": "Hospitalized patients with non-cirrhotic chronic liver disease and COVID-19 (n=231).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:33:57.654807+00:00"}
{"study_id": 102463, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to compare the effects of SGLT2 inhibitors versus DPP4 inhibitors on liver function, specifically focusing on changes in alanine aminotransferase (ALT) and other liver-related markers in patients with type 2 diabetes in Japan.", "results_summary": "The study found that SGLT2 inhibitors significantly reduced ALT, FIB-4 index, and GGT, and increased albumin compared to DPP4 inhibitors, suggesting potential hepatoprotective benefits, including prevention of liver fibrosis. Greater improvements in ALT were observed in subgroups with lower baseline FIB-4 index and HbA1c.", "population_specificity": "Patients with type 2 diabetes in Japan.", "effective_dosage": "Not specified", "study_duration": "1 year", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:33:58.127027+00:00"}
{"study_id": 102462, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine whether measuring hepatitis B core-related antigen (HBcrAg) after nucleos(t)ide analog cessation could stratify the risk of clinical relapse in chronic hepatitis B patients.", "results_summary": "The study found that dynamic measurement of HBcrAg after treatment cessation was predictive of subsequent clinical relapse, with HBcrAg <1,000 U/mL indicating a lower risk. Time-varying HBcrAg levels were a significant risk factor for relapse.", "population_specificity": "Adults with chronic hepatitis B who discontinued entecavir or tenofovir, were HBeAg-negative, and had undetectable HBV DNA at the end of treatment, excluding those with cirrhosis or malignancy.", "effective_dosage": "Not specified", "study_duration": "Median treatment duration was 36.9 months; median post-treatment follow-up was 31.7 months.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:33:58.870681+00:00"}
{"study_id": 102469, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were evaluating the safety and efficacy of BMS-986,205 in combination with nivolumab as first-line therapy for advanced hepatocellular carcinoma (HCC), not specifically studying Alanine.", "results_summary": "The study reported elevated alanine transaminase (ALT) levels in 3 patients as a treatment-related adverse event, but the focus was on the combination therapy's safety and efficacy, not Alanine's effects.", "population_specificity": "Adults with untreated, unresectable/metastatic HCC, Child Pugh A, some with underlying viral hepatitis.", "effective_dosage": "Not specified for Alanine (study used BMS-986,205 at 50-100 mg orally daily).", "study_duration": "Not specified for Alanine (patients received a total of 91 treatment cycles).", "interactions": "None mentioned for Alanine.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:33:59.223698+00:00"}
{"study_id": 102467, "supplement_id": 863, "safety_score": "75", "efficacy_score": 60, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the safety, pharmacokinetics, and preliminary efficacy of LXI-15029, an mTORC1/2 dual inhibitor, in Chinese patients with advanced malignant solid tumors, with a focus on adverse events including increased alanine aminotransferase.", "results_summary": "LXI-15029 was well tolerated, with one dose-limiting toxicity (grade 3 increased alanine aminotransferase) at the highest dose. The disease control rate was 40.0%, and eight patients had stable disease.", "population_specificity": "Chinese patients with advanced, unresectable malignant solid tumors who had failed routine therapy or had no standard treatment.", "effective_dosage": "Ascending doses of 10, 20, 40, 60, 80, 110, and 150 mg orally twice daily.", "study_duration": "Until disease progression or intolerable adverse events (median progression-free survival was 29 days).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:33:59.266315+00:00"}
{"study_id": 102471, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to assess the consistency of liver function test results, including alanine transaminase, between two analyzers (Architect c8000 and Cobas C501).", "results_summary": "The study found a highly significant correlation (r>0.90) between the results of liver function parameters, including alanine transaminase, obtained from the two analyzers.", "population_specificity": "Patients undergoing liver function tests at Dr. Mohammad Hoesin General Hospital, Palembang, South Sumatra, Indonesia.", "effective_dosage": "Not available", "study_duration": "Not applicable (cross-sectional study)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:05.874469+00:00"}
{"study_id": 102470, "supplement_id": 863, "safety_score": "85", "efficacy_score": 90, "quality_score": 88, "study_goal": "The researchers aimed to assess the efficacy and safety of danicopan (ALXN2040), an oral complement factor D inhibitor, as add-on therapy to ravulizumab or eculizumab in patients with PNH and clinically significant extravascular haemolysis.", "results_summary": "Danicopan significantly improved haemoglobin concentrations at week 12 compared to placebo, with no new safety concerns reported. Adverse events were mostly mild to moderate, with no serious adverse events related to the study drug or deaths.", "population_specificity": "Adults (age \u226518 years) with PNH and clinically significant extravascular haemolysis (haemoglobin \u22649\u00b75 g/dL; absolute reticulocyte count \u2265120 \u00d7 10^9/L).", "effective_dosage": "Not specified in the abstract.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:07.230583+00:00"}
{"study_id": 102474, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to assess the efficacy of fecal microbiota transplantation (FMT) in treating type 2 diabetes mellitus (T2DM), including its impact on Alanine Transaminase (ALT) levels.", "results_summary": "The study found that FMT treatment, particularly in combination with other therapies, significantly reduced ALT levels in T2DM patients, indicating potential benefits for liver function. Additionally, FMT improved metabolic markers like PBG, TG, HOMA-IR, TC, and DBP.", "population_specificity": "Patients with type 2 diabetes mellitus.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:07.368594+00:00"}
{"study_id": 102472, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to determine whether exercise training improves liver fibroinflammation, as measured by serum biomarkers like alanine aminotransferase (ALT), without body weight loss in patients with metabolic dysfunction-associated steatohepatitis (MASH).", "results_summary": "Exercise training significantly improved serum biomarkers of liver fibroinflammation, including a \u226517 IU/L reduction in ALT in 53% of participants, compared to 13% in the control group, and improved CK18 levels. ALT reduction correlated with reduced liver fat and PNPLA3 genotype.", "population_specificity": "Patients with metabolic dysfunction-associated steatohepatitis (MASH).", "effective_dosage": "Not specified (exercise intervention: moderate-intensity aerobic training).", "study_duration": "20 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:07.529798+00:00"}
{"study_id": 102475, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine the impact of zinc supplementation on serum alanine aminotransferase (ALT) concentrations and other metabolic parameters in overweight or obese children with nonalcoholic steatohepatitis (NASH).", "results_summary": "Zinc supplementation significantly reduced serum ALT concentrations and high-sensitivity C-reactive protein while increasing HDL-cholesterol, but had no significant effect on aspartate aminotransferase, liver steatosis severity, or other lipid indices compared to placebo.", "population_specificity": "Overweight or obese children aged 10-18 years with NASH.", "effective_dosage": "30 mg/day of elemental zinc.", "study_duration": "16 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:07.848428+00:00"}
{"study_id": 102477, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to identify important predictors, including alanine aminotransferase, for the prognosis of advanced nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy using machine learning algorithms.", "results_summary": "Alanine aminotransferase was identified as one of the six most important predictors for unfavorable prognosis in advanced nasopharyngeal carcinoma patients, as determined by the random forest model, which showed the best predictive performance (AUC: 0.753).", "population_specificity": "427 advanced nasopharyngeal carcinoma patients (stage III-IV) treated with intensity-modulated radiotherapy in Meizhou People's Hospital, China.", "effective_dosage": "Not available", "study_duration": "Average follow-up period of 7.16 years (from July 2020 to March 2021).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:09.225586+00:00"}
{"study_id": 102476, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to determine the normal reference interval for thiamine concentrations in healthy dogs and investigate the prevalence of thiamine deficiency in critically ill dogs with and without sepsis.", "results_summary": "The study found that thiamine concentrations were significantly lower in septic dogs compared to healthy controls, with 27.3% of septic dogs showing absolute thiamine deficiency. No significant differences were found between septic and nonseptic critically ill dogs or between healthy dogs and nonseptic critically ill dogs.", "population_specificity": "109 dogs (40 healthy, 33 septic, 36 nonseptic critically ill)", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:09.289999+00:00"}
{"study_id": 102478, "supplement_id": 863, "safety_score": "85", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the minimum effective dose of prophylactic acetaminophen to close the ductus arteriosus and assess its safety and tolerability in extremely preterm infants.", "results_summary": "The study found that acetaminophen at a dose of 25 mg/kg loading dose followed by 10 mg/kg/6 h for 5 days was effective in closing the ductus arteriosus in 65.5% of cases, with no adverse effects on hepatic function or hemodynamics.", "population_specificity": "Extremely preterm infants at 23-26 weeks of gestation.", "effective_dosage": "25 mg/kg loading dose, then 10 mg/kg every 6 hours.", "study_duration": "5 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:09.932441+00:00"}
{"study_id": 102480, "supplement_id": 863, "safety_score": "70", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the safety and efficacy of etranacogene dezaparvovec-drlb, an AAV5 vector therapy, in patients with congenital hemophilia B.", "results_summary": "The therapy resulted in stable, sustained near-normal to normal FIX levels, significantly reducing bleeding and FIX prophylaxis needs. However, 17% of patients required corticosteroid therapy for ALT elevation.", "population_specificity": "Patients with congenital hemophilia B (Factor IX deficiency).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:15.126490+00:00"}
{"study_id": 102479, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the treatment effects of various interventions, including glucagon-like peptide-1 receptor agonists (GLP-1RAs), for NAFLD combined with T2DM, but did not specifically focus on Alanine.", "results_summary": "The study did not assess Alanine's effects; it highlighted exenatide and liraglutide as effective interventions for reducing liver fat content, controlling glycemia, and improving liver function in NAFLD with T2DM.", "population_specificity": "Patients with NAFLD combined with T2DM (1,589 participants across 24 studies).", "effective_dosage": "Not available (Alanine not assessed).", "study_duration": "Not specified (Alanine not assessed).", "interactions": "None mentioned (Alanine not assessed).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:15.127176+00:00"}
{"study_id": 102481, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 85, "study_goal": "The researchers aimed to determine whether remote ischemic preconditioning could reduce ischemia-reperfusion injury in patients with chronic liver disease undergoing hepatectomy.", "results_summary": "Remote ischemic preconditioning did not significantly reduce postoperative transaminase levels or affect clinical outcomes and biomarkers in patients with chronic liver disease.", "population_specificity": "102 patients with chronic liver disease undergoing hepatectomy (median age 69.5 years, 67.7% male).", "effective_dosage": "3 cycles of 10-minute ischemia and reperfusion of the upper extremity.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:15.730712+00:00"}
{"study_id": 102482, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the 3-year safety profile of bimekizumab (BKZ) in patients with moderate-to-severe plaque psoriasis, not specifically Alanine.", "results_summary": "The study found that BKZ had a manageable safety profile over 3 years, with common adverse events like nasopharyngitis and oral candidiasis, but no new safety signals emerged with prolonged exposure. Alanine aminotransferase elevations (>5\u00d7 upper limit of normal) were rare (0.6/100 PY).", "population_specificity": "Patients with moderate-to-severe plaque psoriasis.", "effective_dosage": "Not specified for Alanine.", "study_duration": "3 years.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:16.427818+00:00"}
{"study_id": 102483, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to investigate the safety of inactivated COVID-19 vaccination during the peri-pregnancy period, including monitoring serum alanine transaminase (ALT) levels.", "results_summary": "The study found no significant difference in maternal or neonatal adverse events between vaccinated and control groups, except for higher ALT levels in the vaccine group during the first trimester. The results were robust across sensitivity analyses.", "population_specificity": "Pregnant women in China receiving pregnancy care between January 1, 2021, and December 31, 2021.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:17.829983+00:00"}
{"study_id": 102486, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to investigate clinical findings, treatment strategies, and outcomes in dogs with hepatic abscessation, including the role of alanine aminotransferase as a diagnostic marker.", "results_summary": "The study found increased alanine aminotransferase levels in 40 of 50 dogs with hepatic abscessation, indicating liver involvement, but did not assess alanine's therapeutic or supplemental effects.", "population_specificity": "Fifty-six client-owned dogs with confirmed hepatic abscessation.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:17.865269+00:00"}
{"study_id": 102485, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to determine the efficacy and safety of stem cell transplantation (SCT) in treating liver cirrhosis, including its effects on alanine aminotransferase (ALT) levels.", "results_summary": "The study found no significant beneficial effects of SCT on ALT levels in patients with liver cirrhosis, though it did improve other clinical outcomes like MELD score and platelet count.", "population_specificity": "Patients with liver cirrhosis", "effective_dosage": "Not specified", "study_duration": "Outcomes were assessed at 1 month and 3 months post-intervention.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:17.891879+00:00"}
{"study_id": 102484, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 85, "study_goal": "The researchers aimed to characterize changes in alanine and other metabolite concentrations in critically ill patients receiving intermittent versus continuous enteral feeding.", "results_summary": "The study found a logfold decrease in alanine abundance (-0.594) over time, with increasing severity of organ failure related to changes in alanine levels (p = 0.005). No broad metabolite patterns distinguished between feeding regimens.", "population_specificity": "Critically ill patients in intensive care units.", "effective_dosage": "Not specified (feeding regimen: 6x/day intermittent vs. continuous).", "study_duration": "10 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:18.612383+00:00"}
{"study_id": 102488, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety and adverse events associated with oral antifungals, including potential effects on alanine transaminase levels.", "results_summary": "The study identified adverse events related to oral antifungals, including hepatotoxicity and alanine transaminase elevations, but did not specifically assess Alanine's safety or efficacy.", "population_specificity": "Patients with moderate-severe onychomycosis treated with oral antifungals.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "Cytochrome-p450 interactions with terbinafine, itraconazole, and fluconazole were noted.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:23.480414+00:00"}
{"study_id": 102490, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "To investigate the efficacy and safety of semaglutide in patients with NAFLD.", "results_summary": "Semaglutide increased the likelihood of NASH resolution and improved liver fibrosis, while maintaining a well-tolerated safety profile. The treatment was effective for NAFLD without significant adverse effects.", "population_specificity": "Patients with non-alcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:23.545993+00:00"}
{"study_id": 102487, "supplement_id": 863, "safety_score": "75", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to investigate the safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary antitumor activity of QL1604, a monoclonal antibody, in patients with advanced or metastatic solid tumors.", "results_summary": "QL1604 showed favorable safety and pharmacokinetic profiles, with partial responses in 20% of patients. The most frequent adverse events included fatigue, anemia, and increased liver enzymes, but the maximum tolerated dose was not reached.", "population_specificity": "Patients with advanced or metastatic solid tumors who failed or had no standard therapies available.", "effective_dosage": "0.3 mg/kg, 1 mg/kg, 3 mg/kg, and 10 mg/kg intravenously every 2 weeks (Q2W) or 3 mg/kg every 3 weeks (Q3W), and a fixed dose of 200 mg Q3W.", "study_duration": "Not explicitly stated in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:25.498968+00:00"}
{"study_id": 102489, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study aimed to assess the antitumor activity and safety of dostarlimab in patients with advanced or recurrent dMMR solid tumors, not specifically Alanine.", "results_summary": "The study found dostarlimab demonstrated rapid, robust, and durable antitumor activity in patients with diverse dMMR solid tumors, with an objective response rate of 44.0%. Alanine aminotransferase increase was noted as a frequent immune-related adverse event (5.8%).", "population_specificity": "Patients with advanced or recurrent dMMR and MSI-H or POLE-altered solid tumors, including endometrial cancer (43.1%), colorectal cancer (32.1%), and other tumor types (24.8%).", "effective_dosage": "Not applicable (study focused on dostarlimab, not Alanine).", "study_duration": "Median follow-up of 27.7 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:25.508995+00:00"}
{"study_id": 102493, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to review the hepatic complications associated with AAV vector-based gene therapy, particularly focusing on raised ALT (alanine aminotransferase) levels as a side effect.", "results_summary": "The study highlights that AAV-based gene therapy can lead to hepatic reactions, with elevated ALT and AST levels being common side effects, though the underlying mechanisms and long-term risks remain unclear. The liver community is increasingly involved in managing these complications.", "population_specificity": "Patients undergoing liver-directed AAV vector-based gene therapy, particularly for conditions like haemophilia A and B.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:27.066924+00:00"}
{"study_id": 102495, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to compare the effectiveness of seven interventions, including combinations involving Alanine-related outcomes (e.g., normalizing alanine aminotransferase levels), for treating chronic hepatitis D.", "results_summary": "The study found that IFN, IFN + BLV, and IFN + NAs were effective in clearing HDV RNA and normalizing alanine aminotransferase levels, with IFN + BLV showing strong synergistic effects. However, IFN and IFN + NAs had high viral relapse rates at 24 weeks post-treatment, and none of the regimens significantly improved liver histology.", "population_specificity": "814 patients with chronic hepatitis D across 14 randomized controlled trials.", "effective_dosage": "Not specified", "study_duration": "24 weeks of follow-up", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:28.588984+00:00"}
{"study_id": 102491, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the association between Dysosmobacter welbionis abundance and metabolic health, including its correlation with alanine aminotransferase (ALT) levels in humans with obesity and diabetes.", "results_summary": "D. welbionis abundance was negatively correlated with ALT levels, suggesting a potential link between this gut bacterium and improved liver health in individuals with obesity and type 2 diabetes. The study also found that metformin treatment increased D. welbionis levels, but prebiotic intervention did not affect its abundance.", "population_specificity": "106 human participants with obesity and diabetes, stratified by metformin treatment.", "effective_dosage": "Not specified for alanine or D. welbionis.", "study_duration": "Not specified for the human intervention.", "interactions": "Metformin treatment influenced D. welbionis abundance, but no direct interactions with alanine were mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:28.716739+00:00"}
{"study_id": 102494, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effects of liver dose-volume on changes in liver function tests (LFTs), including alanine aminotransferase (ALT), in patients undergoing right breast radiotherapy.", "results_summary": "The study found a median increase of up to 15% in ALT and other LFTs post-radiotherapy, indicating acute liver damage, despite no systemic treatment or risk factors. Attention to liver doses during planning and regular LFT follow-up was emphasized.", "population_specificity": "100 patients (median age 56) treated for right breast cancer across three centers.", "effective_dosage": "Not applicable (study focused on radiotherapy doses, not alanine supplementation).", "study_duration": "Radiotherapy was administered over 25 fractions (total dose 50 Gy), with a boost dose (10-16 Gy) for some patients.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:29.126845+00:00"}
{"study_id": 102498, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to identify metabolites, including alanine, that could serve as potential biomarkers for severe traumatic brain injury (sTBI) and examine their effects on metabolic pathways.", "results_summary": "The study found that alanine levels decreased in adults following sTBI, suggesting its involvement in altered metabolic pathways, particularly those related to amino acid metabolism. However, the study noted significant ambiguity in the literature regarding metabolic profiles due to varying study designs and methodologies.", "population_specificity": "Adults with severe traumatic brain injury (sTBI).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:31.804100+00:00"}
{"study_id": 102499, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to evaluate the feasibility, efficacy, and safety of concurrent chemoradiotherapy with weekly low-dose carboplatin for cisplatin-ineligible patients with advanced head and neck squamous cell carcinoma (HNSCC).", "results_summary": "The study found a 90% completion rate of CCRT and a 90% overall response rate. Grade 3 adverse events included oral/pharyngeal mucositis (47%), leukocytopenia (20%), and neutropenia (10%), with one Grade 4 adverse event (elevated alanine aminotransferase).", "population_specificity": "Adult patients (age \u2265 20 years) with HNSCC who were cisplatin-ineligible due to age (\u2265 75 years with eGFR \u2265 40 mL/min) or renal dysfunction (< 75 years with eGFR 30-60 mL/min).", "effective_dosage": "Carboplatin administered weekly (AUC = 2.0) for up to seven cycles.", "study_duration": "Concurrent with radiotherapy (70 Gy/35 Fr).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:37.511973+00:00"}
{"study_id": 102504, "supplement_id": 863, "safety_score": "75", "efficacy_score": 80, "quality_score": 85, "study_goal": "The researchers aimed to compare the efficacy and safety of deferiprone versus deferoxamine in reducing iron overload in pediatric patients with sickle cell disease (SCD) or other anemias.", "results_summary": "Deferiprone was comparable to deferoxamine in reducing liver iron concentration and improving cardiac T2*, with no new safety concerns observed. Common adverse events included upper abdominal pain, vomiting, and increased ALT/AST, but all resolved, mostly without intervention.", "population_specificity": "Pediatric patients (\u226417 years) with SCD or other anemias.", "effective_dosage": "Not specified in the abstract.", "study_duration": "12 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:38.044002+00:00"}
{"study_id": 102505, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effects of caper fruit on glycemic control, lipid profile, liver enzymes, and body mass in patients with metabolic disorders.", "results_summary": "The study found that caper fruit supplementation significantly reduced ALT levels, increased HDL, and decreased weight, with modest effects on other lipid and glycemic markers.", "population_specificity": "Adults with non-alcoholic fatty liver disease (NAFLD), Type-2-Diabetes (T2D), metabolic syndrome, and hyperlipidemia.", "effective_dosage": "Not specified", "study_duration": "2 to 12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:38.230320+00:00"}
{"study_id": 102503, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to investigate the efficacy, safety, and biomarkers of a triple combination therapy (FOLFOX, lenvatinib, and toripalimab) in advanced hepatocellular carcinoma (HCC) with extrahepatic metastasis, not specifically focused on Alanine.", "results_summary": "The study found increased alanine aminotransferase levels as a common adverse event but did not assess Alanine's efficacy or safety as a supplement. The primary focus was on the combination therapy's antitumor activity and biomarker analysis.", "population_specificity": "Patients with advanced hepatocellular carcinoma (HCC) with extrahepatic metastasis.", "effective_dosage": "Not specified for Alanine.", "study_duration": "Not specified for Alanine.", "interactions": "None mentioned for Alanine.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:39.482411+00:00"}
{"study_id": 102501, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to compare the relapse rates of hepatitis B virus (HBV) in patients receiving short finite intervals (6 months vs. 12 months) of nucleos(t)ide analogue therapy after chemotherapy cessation, focusing on alanine aminotransferase levels as part of clinical relapse criteria.", "results_summary": "The study found no significant difference in virological or clinical relapse rates between 6-month and 12-month treatment durations. High pretreatment HBV DNA and end-of-treatment HBsAg levels were predictors of virological relapse.", "population_specificity": "Patients with hepatitis B receiving chemotherapy, stratified by low (<2000 IU/ml) or high (\u22652000 IU/ml) HBV DNA levels.", "effective_dosage": "Not specified (tenofovir or entecavir used, but exact dosages not detailed).", "study_duration": "6 months or 12 months post-chemotherapy cessation.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:39.771307+00:00"}
{"study_id": 102506, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the effects of conjugated linoleic acid (CLA) supplementation on glycemic control, adipokines, cytokines, malondialdehyde (MDA), and liver function enzymes in patients at risk of cardiovascular disease.", "results_summary": "CLA supplementation increased fasting blood glucose (FBG) and aspartate aminotransferase (AST) but decreased leptin and interleukin-6 (IL-6). No significant effects were observed on HbA1c, HOMA-IR, CRP, TNF-\u03b1, or alanine aminotransferase (ALT).", "population_specificity": "Patients at risk of cardiovascular disease", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:40.816902+00:00"}
{"study_id": 102496, "supplement_id": 863, "safety_score": "75", "efficacy_score": 80, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety and efficacy of giroctocogene fitelparvovec, an AAV vector-based gene therapy, in increasing endogenous FVIII production in patients with severe hemophilia A, with a focus on treatment-related adverse events including alanine aminotransferase increases.", "results_summary": "The study found that giroctocogene fitelparvovec was generally well-tolerated, with increases in alanine aminotransferase being the most common treatment-related adverse event, which resolved with corticosteroid administration. At the highest dose, mean FVIII activity levels were 42.6% at week 52 and 25.4% at week 104, indicating clinically meaningful FVIII activity.", "population_specificity": "Male participants with severe hemophilia A.", "effective_dosage": "Single IV dose of 3 \u00d7 10\u00b9\u00b3 vg/kg (highest dose level).", "study_duration": "Follow-up up to 214 weeks after treatment.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:45.087683+00:00"}
{"study_id": 102509, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to compare sex differences in treatment outcomes (virologic, biochemical, complete response, and HCC incidence) among hepatitis B patients receiving nucleos(t)ide analogs.", "results_summary": "Females had similar virologic response and HCC incidence rates but lower biochemical and complete response rates compared to males. Male sex was associated with a higher likelihood of clinical remission and biochemical response.", "population_specificity": "Treatment-na\u00efve adult hepatitis B patients (1250 female, 2138 male) from 22 sites globally.", "effective_dosage": "Not specified", "study_duration": "5-year follow-up", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:45.536258+00:00"}
{"study_id": 102508, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to assess the spectrum of adverse events associated with antibody-drug conjugates in anticancer treatment, including effects on alanine aminotransferase levels.", "results_summary": "The study found that antibody-drug conjugates were associated with a higher risk of increased alanine aminotransferase (OR = 2.51, 95% CI = 1.84 to 3.40), indicating potential liver-related toxicity, but no increase in high-grade adverse events was observed.", "population_specificity": "10,075 patients involved in randomized controlled trials evaluating antibody-drug conjugates for anticancer treatment.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:45.912710+00:00"}
{"study_id": 102510, "supplement_id": 863, "safety_score": "70", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the efficacy and safety of aldafermin (an FGF19 analog) in patients with compensated NASH cirrhosis, focusing on liver fibrosis improvement.", "results_summary": "Aldafermin 3 mg significantly reduced Enhanced Liver Fibrosis compared to placebo, with 23% of patients achieving fibrosis improvement \u22651 stage. Adverse events like diarrhea were more frequent in higher-dose groups, but discontinuation rates due to treatment-related events were low.", "population_specificity": "Patients with compensated NASH cirrhosis (n=160).", "effective_dosage": "0.3 mg (discontinued), 1 mg, and 3 mg doses administered.", "study_duration": "48 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:46.929921+00:00"}
{"study_id": 102511, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 88, "study_goal": "The researchers aimed to evaluate the effect of dapagliflozin on liver fat content (LFC) and pancreatic fat content (PFC) in patients with type 2 diabetes (T2D) and non-alcoholic fatty liver disease (NAFLD).", "results_summary": "Dapagliflozin significantly reduced LFC and PFC compared to controls and improved serum levels of ALT, TNF-\u03b1, and IL-6, indicating potential benefits for NAFLD treatment.", "population_specificity": "84 patients with T2D and NAFLD.", "effective_dosage": "Not specified in the abstract.", "study_duration": "24 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:48.179061+00:00"}
{"study_id": 102513, "supplement_id": 863, "safety_score": "65", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the efficacy and safety of 24 weeks of semaglutide treatment in patients with NAFLD or NASH, focusing on changes in serum alanine transaminase levels and other liver and metabolic parameters.", "results_summary": "Semaglutide significantly reduced serum alanine transaminase and aspartate transaminase levels, improved liver fat content and stiffness, and enhanced metabolic parameters, but increased the risk of gastrointestinal and gallbladder-related adverse events.", "population_specificity": "Patients with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH).", "effective_dosage": "Not specified in the abstract.", "study_duration": "24 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:49.861013+00:00"}
{"study_id": 102512, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to assess the prevalence and metabolic characteristics of lean/non-obese nonalcoholic fatty liver disease (NAFLD) in China, including the role of alanine transaminase levels.", "results_summary": "The study found that lean/non-obese NAFLD patients had lower alanine transaminase levels (30.28 IU/L) compared to overweight/obese NAFLD patients (33.12 IU/L), indicating a better metabolic profile in the former group. The prevalence of NAFLD in lean/non-obese Chinese adults was 8.98% for lean and 13.77% for non-obese, showing an increasing trend.", "population_specificity": "229,091 lean/non-obese Chinese adults, including 22,641 diagnosed with NAFLD.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:50.143718+00:00"}
{"study_id": 102514, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 88, "study_goal": "The researchers aimed to evaluate the effect of n-3 polyunsaturated fatty acids (PUFAs) in parenteral nutrition on liver function, inflammatory markers, and clinical outcomes in patients undergoing liver surgery.", "results_summary": "The study found that n-3 PUFAs significantly improved liver function (reduced AST and ALT levels), decreased inflammation (lower IL-6 and white cell count), increased albumin levels, reduced infection complications, and shortened hospital stays compared to controls. No significant differences were observed in total bilirubin, TNF-\u03b1, IL-2, immunoglobulins, CD3, biliary leakage, or mortality.", "population_specificity": "Patients undergoing liver surgery receiving parenteral nutrition.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:53.415830+00:00"}
{"study_id": 102515, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The study aimed to evaluate the efficacy and safety of combining nivolumab, abemaciclib, and either fulvestrant or letrozole in treating HR-positive HER2-negative metastatic breast cancer, not specifically focused on Alanine.", "results_summary": "The study reported elevated alanine aminotransferase levels as a common adverse event, indicating potential liver toxicity, but did not assess Alanine's direct effects or benefits.", "population_specificity": "Patients with HR-positive HER2-negative metastatic breast cancer (n=17).", "effective_dosage": "Not applicable (Alanine not a focus of the study).", "study_duration": "From June 2019 to July 2020 (early termination).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:53.965450+00:00"}
{"study_id": 102517, "supplement_id": 863, "safety_score": "85", "efficacy_score": 90, "quality_score": 88, "study_goal": "The researchers aimed to characterize the relationship between pegozafermin dosing, exposure, and effects on hepatic fat fraction (HFF) reduction in patients with NASH.", "results_summary": "Pegozafermin significantly reduced HFF, with efficacy linked to exposure, and demonstrated a favorable safety profile. Dosing regimens of 30 mg weekly and 44 mg every 2 weeks were effective for HFF reduction, suggesting potential fibrosis regression.", "population_specificity": "Patients with nonalcoholic steatohepatitis (NASH).", "effective_dosage": "30 mg weekly (q.w.) and 44 mg every 2 weeks (q2w).", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:55.199144+00:00"}
{"study_id": 102516, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 75, "study_goal": "The researchers investigated the efficacy and safety of nivolumab maintenance therapy following platinum-based chemotherapy in EGFR-mutant NSCLC patients after EGFR-TKI failure, with a focus on progression-free survival and adverse events, including increased alanine aminotransferase.", "results_summary": "The study found that nivolumab maintenance therapy did not show clinical benefits, with a median PFS of 1.7 months and a 15.4% incidence of grade 3-4 treatment-related adverse events, including increased alanine aminotransferase in 7.7% of patients.", "population_specificity": "Patients aged 18 or older with EGFR-mutant NSCLC that progressed after first- or second-line EGFR-TKI therapy.", "effective_dosage": "240 mg of nivolumab every 2 weeks for 3 months, followed by 480 mg every 4 weeks.", "study_duration": "Until disease progression or unacceptable toxic effects occurred.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:56.120353+00:00"}
{"study_id": 102519, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the sensitivity and specificity of alanine-based amino acid ratio combinations as biomarkers for early identification of pyruvate dehydrogenase complex deficiency (PDCD).", "results_summary": "The study found that specific alanine-based amino acid ratio combinations (Ala/Lys \u22653.0 and Ala/Leu \u22655.0) effectively discriminated PDCD from other metabolic disorders with 100% sensitivity and ~85% specificity. These ratios were more sensitive than alanine alone or combinations with proline.", "population_specificity": "Patients with molecularly or enzymatically confirmed PDCD, other inborn errors of metabolism, and non-IEM conditions (201 subjects with a broad age range).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:57.863923+00:00"}
{"study_id": 102518, "supplement_id": 863, "safety_score": "30", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the glucagon/GLP-1 receptor co-agonist NN1177, including its effects on weight loss and potential adverse events related to alanine aminotransferase levels.", "results_summary": "The study found clinically relevant weight loss (up to 12.6% at week 12) but observed several safety signals, including increased alanine aminotransferase, suggesting potential liver-related adverse effects. The treatment was associated with dose-dependent weight loss but also unexpected safety concerns.", "population_specificity": "Adults with overweight or obesity.", "effective_dosage": "Escalating doses of 200, 600, 1300, 1900, 2800, 4200, and 6000 \u03bcg (MAD trial); single doses of 10, 40, 120, 350, 700, and 1100 \u03bcg (FHD/SAD trial).", "study_duration": "12 weeks (MAD trial); single-dose administration (FHD/SAD trial).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:58.839352+00:00"}
{"study_id": 102500, "supplement_id": 863, "safety_score": "65", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to confirm the superiority of aponermin (a circularly permuted tumor necrosis factor-related apoptosis-inducing ligand) plus thalidomide and dexamethasone over placebo plus thalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (RRMM).", "results_summary": "The study found that aponermin significantly improved progression-free survival (5.5 vs. 3.1 months), overall survival (22.4 vs. 16.4 months), and overall response rates compared to placebo, though it caused transient hepatotoxicity (elevated alanine transaminase, aspartate transaminase, or lactate dehydrogenase levels) in some patients.", "population_specificity": "Patients with relapsed or refractory multiple myeloma who had previously received at least two regimens.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:58.895632+00:00"}
{"study_id": 102521, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to validate a severity grading system for post-KPE cholangitis and compare the efficacy of different antibiotic treatments, including their effects on alanine aminotransferase levels.", "results_summary": "In severe cholangitis, MEPM+IVIG reduced alanine aminotransferase levels and improved liver function compared to MEPM alone, but no significant differences were observed in recurrence rate, jaundice clearance, or native liver survival.", "population_specificity": "Patients with post-Kasai portoenterostomy cholangitis.", "effective_dosage": "Not specified for alanine aminotransferase-related outcomes.", "study_duration": "Follow-up at 1-month, 3-month, and 6-month intervals.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:01.660196+00:00"}
{"study_id": 102522, "supplement_id": 863, "safety_score": "80", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the efficacy and safety of cadonilimab (a bispecific antibody targeting PD-1 and CTLA-4) in patients with previously treated metastatic non-small-cell lung cancer (NSCLC), including its impact on alanine aminotransferase levels.", "results_summary": "The study found that cadonilimab had limited efficacy, with an objective response rate of 10% in immunotherapy-na\u00efve patients and no responders in those with primary or acquired resistance to immunotherapy. Alanine aminotransferase increase was reported as a grade 3-4 treatment-related adverse event in 1.9% of patients.", "population_specificity": "Patients with previously treated metastatic NSCLC, divided into three cohorts based on prior immunotherapy response (na\u00efve, primary resistance, acquired resistance).", "effective_dosage": "6 mg/kg intravenously every 2 weeks.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:03.722208+00:00"}
{"study_id": 102524, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to assess the effects of cholecalciferol supplementation on serum inflammatory biomarkers and liver function, including alanine aminotransferase (ALT), in NAFLD patients with type 2 diabetes.", "results_summary": "Group 2 (cholecalciferol) showed significant reductions in ALT, lipid profile measures, and inflammatory markers compared to baseline and placebo, while no significant changes were observed in glycemic index or AST levels.", "population_specificity": "100 patients with NAFLD and type 2 diabetes mellitus.", "effective_dosage": "Not specified (high oral loading dose of cholecalciferol).", "study_duration": "4 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:03.724986+00:00"}
{"study_id": 102525, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the efficacy and safety of TACE plus lenvatinib in treating advanced hepatocellular carcinoma (HCC), not specifically Alanine.", "results_summary": "The study found that TACE plus lenvatinib improved objective response rates, disease control rates, and survival rates compared to TACE or lenvatinib alone, but increased adverse events like hypertension and elevated liver enzymes.", "population_specificity": "Patients with advanced hepatocellular carcinoma (HCC).", "effective_dosage": "Not mentioned (focus was on TACE plus lenvatinib, not Alanine).", "study_duration": "Not specified (study duration not detailed in the abstract).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:04.176996+00:00"}
{"study_id": 102526, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the impact of DAA therapy on metabolic changes, renal function, and anemia risk in patients with HCV infection, including effects on alanine aminotransferase levels.", "results_summary": "DAA therapy significantly reduced alanine aminotransferase levels, indicating improved liver function, but also led to decreased hemoglobin and hematocrit levels, increasing anemia risk. Most metabolic changes were not genotype-dependent, except for Hb, HCT, and HbA1C.", "population_specificity": "280 patients with HCV infection who achieved sustained virologic response after DAA therapy without ribavirin.", "effective_dosage": "Not specified", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:06.497040+00:00"}
{"study_id": 102528, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the efficacy and safety of metformin in pediatric patients with non-alcoholic fatty liver disease (NAFLD), specifically focusing on its impact on alanine aminotransferase (ALT) levels.", "results_summary": "The meta-analysis found that metformin did not achieve a statistically significant improvement in ALT levels in pediatric NAFLD patients, with a weighted mean difference of -1.55 IU/L (95% CI: -5.38 to 2.28).", "population_specificity": "Pediatric patients with non-alcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:06.898097+00:00"}
{"study_id": 102527, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The study aimed to compare the clinical effectiveness of dulaglutide and semaglutide in Japanese patients with type 2 diabetes, focusing on glycemic control and metabolic parameters.", "results_summary": "Semaglutide showed superior efficacy in reducing HbA1c, body mass index, visceral fat area, and liver fat percentage compared to dulaglutide. However, semaglutide was associated with higher gastrointestinal side effects, while dulaglutide had better quality-of-life scores related to pain and gastrointestinal symptoms.", "population_specificity": "Japanese patients with type 2 diabetes (HbA1c \u22657%).", "effective_dosage": "Not specified (doses approved for use in Japan).", "study_duration": "24 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:06.957297+00:00"}
{"study_id": 102520, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate the effect of vitamin E supplementation on serum alanine aminotransferase (ALT) levels in patients with non-alcoholic fatty liver disease (NAFLD).", "results_summary": "Vitamin E supplementation at 400 IU/day and above significantly reduced ALT levels compared to placebo or no intervention, with greater reductions observed in non-Asian countries. AST levels also decreased, though the effect was smaller and less precise in non-Asian studies.", "population_specificity": "Patients with NAFLD, including both Asian and non-Asian populations.", "effective_dosage": "400 IU/day and above.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:08.450740+00:00"}
{"study_id": 102529, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to evaluate the efficacy and safety of combining CHRT-CHF (a traditional Chinese medicine principle) with TACE in treating primary liver cancer (PLC).", "results_summary": "The combined therapy showed significantly better survival rates (1- and 2-year), objective response rate (ORR), and disease control rate (DCR) compared to TACE alone. It also reduced liver function indicators (AST, ALT), AFP levels, and postembolization syndrome (PES).", "population_specificity": "Patients with unresected primary liver cancer (PLC) undergoing TACE.", "effective_dosage": "Optimal proportion of CHRT-CHF was 20-30% for efficacy and \u226540% for reducing PES.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:10.367495+00:00"}
{"study_id": 102531, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to update the epidemiology, clinical, and economic outcomes of patients diagnosed with chronic hepatitis B (CHB) infection in Taiwan, including the role of alanine aminotransferase laboratory tests in diagnosis.", "results_summary": "The study found that the prevalence of diagnosed CHB increased over the study period, with higher rates in older age groups and men. Complications such as cirrhosis and hepatocellular carcinoma were observed, and healthcare costs were higher with increasing disease severity.", "population_specificity": "Patients diagnosed with chronic hepatitis B (CHB) in Taiwan between 2010 and 2019.", "effective_dosage": "Not specified", "study_duration": "Median follow-up period of 6.42 years", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:12.051558+00:00"}
{"study_id": 102530, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to compare the hepatoprotective effects of propofol versus sevoflurane anesthesia on postoperative liver damage, as measured by alanine transaminase (ALT) levels, in patients undergoing hepatectomy with the Pringle maneuver.", "results_summary": "Propofol anesthesia resulted in significantly lower postoperative ALT levels compared to sevoflurane, indicating a greater hepatoprotective effect during hepatectomy with the Pringle maneuver. The hazard ratios for ALT reduction were statistically significant, supporting propofol's superior efficacy in minimizing liver damage.", "population_specificity": "56 patients undergoing elective hepatectomies with the Pringle maneuver due to metastatic hepatic masses.", "effective_dosage": "Not specified", "study_duration": "Duration of the surgical intervention (not specified)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:12.882589+00:00"}
{"study_id": 102532, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to compare the toxicity profiles of different ALK-TKIs, including their effects on alanine aminotransferase (ALT) levels, to guide clinical decision-making in treating advanced non-small cell lung cancer.", "results_summary": "The study found that elevated ALT or AST levels were among the most frequent adverse events associated with crizotinib and brigatinib, but the toxicity spectra varied across ALK-TKIs. Alectinib showed the lowest rate of grade 3-4 adverse events (16.2%), suggesting it might be the safest option.", "population_specificity": "Patients with advanced non-small cell lung cancer (3,353 participants across 13 RCTs).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:13.182814+00:00"}
{"study_id": 102534, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to identify predictive clinical factors, including alanine transaminase levels, for pediatric choledocholithiasis using a machine learning algorithm.", "results_summary": "Elevated serum alanine transaminase levels were associated with choledocholithiasis in pediatric patients, and this factor was included in a highly predictive 9-feature machine learning model (AUC 0.935).", "population_specificity": "Children under 18 years who underwent cholecystectomy at 10 pediatric institutions (2016\u20132019).", "effective_dosage": "Not available", "study_duration": "Not applicable (retrospective study)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:14.680737+00:00"}
{"study_id": 102533, "supplement_id": 863, "safety_score": "75", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the safety and efficacy of a single intravenous infusion of an adeno-associated virus serotype 8 vector encoding UGT1A1 (GNT0003) in patients with Crigler-Najjar syndrome.", "results_summary": "The study found no serious adverse events, with common side effects being headache and elevated liver enzymes. Higher doses of GNT0003 led to sustained reductions in bilirubin levels, allowing patients to discontinue phototherapy by the end of follow-up.", "population_specificity": "Patients with Crigler-Najjar syndrome undergoing phototherapy.", "effective_dosage": "Two patients received 2\u00d710^12 vector genomes/kg, and three received 5\u00d710^12 vector genomes/kg (single infusion).", "study_duration": "Follow-up ranged from 78 to 80 weeks post-infusion.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:16.424823+00:00"}
{"study_id": 102535, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 85, "study_goal": "The researchers aimed to compare the efficacy and safety of brigatinib versus alectinib in patients with ALK+ NSCLC who had progressed on crizotinib, focusing on progression-free survival.", "results_summary": "The study found no significant difference in progression-free survival between brigatinib and alectinib, with median PFS of 19.3 and 19.2 months, respectively. Elevated alanine aminotransferase levels were observed in 40% of brigatinib-treated patients and 36% of alectinib-treated patients.", "population_specificity": "Patients with advanced ALK+ NSCLC who had disease progression on crizotinib.", "effective_dosage": "Brigatinib 180 mg once daily (with a 7-day lead-in at 90 mg); alectinib 600 mg twice daily.", "study_duration": "Not explicitly stated in the abstract.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:16.550755+00:00"}
{"study_id": 102536, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers sought to determine the effect of bariatric surgery on liver function, particularly focusing on alanine aminotransferase (ALT) levels, in people with obesity.", "results_summary": "Bariatric surgery significantly reduced ALT and GGT levels in patients with elevated baseline ALT, with sustained improvements over 60 months. The surgery also improved metabolic outcomes like HbA1c, blood pressure, and cholesterol levels.", "population_specificity": "511 patients with obesity who underwent bariatric surgery (71 sleeve gastrectomy, 440 gastric bypass).", "effective_dosage": "Not specified", "study_duration": "60 months of follow-up", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:16.751419+00:00"}
{"study_id": 102537, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers compared demographic, laboratory data, and outcomes of COVID-19 patients infected with different SARS-CoV-2 variants (Alpha, Delta, and Omicron), including levels of alanine transaminase (ALT).", "results_summary": "The study found that during the Omicron wave, hospitalized patients had lower median levels of ALT compared to other variants, suggesting less severe liver involvement. However, the study did not focus on ALT as a primary outcome.", "population_specificity": "Hospitalized COVID-19 patients in Iran infected with Alpha, Delta, or Omicron variants.", "effective_dosage": "Not available", "study_duration": "Not applicable (retrospective study)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:18.435289+00:00"}
{"study_id": 102541, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to determine the efficacy of ginger supplementation versus placebo in reducing alanine aminotransferase (ALT) and other markers in patients with non-alcoholic fatty liver disease.", "results_summary": "Ginger supplementation significantly reduced ALT and HOMA-IR but showed no significant impact on AST, total cholesterol, LDL, or BMI.", "population_specificity": "177 patients with non-alcoholic fatty liver disease.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:19.828543+00:00"}
{"study_id": 102540, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the effects of gut microbiome-targeted therapies (probiotics, prebiotics, synbiotics) on liver enzymes, including alanine aminotransferase (ALT), in patients with NAFLD.", "results_summary": "The study found that microbiome-targeted therapies significantly reduced ALT levels in NAFLD patients, with probiotics and synbiotics showing the most pronounced effects, while prebiotics had no significant impact.", "population_specificity": "Patients with nonalcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:20.487519+00:00"}
{"study_id": 102538, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the justification of eligibility criteria in acute leukemia trials, including AST/ALT (alanine aminotransferase) levels, and their concordance with drug safety data.", "results_summary": "The study found limited drug safety justifications for acute leukemia eligibility criteria, with AST/ALT criteria being concordant with safety data in 58.8% of trials, but criteria limits were more restrictive than safety-based limits in 51.4% of trials.", "population_specificity": "Patients eligible for front-line phase II and/or III acute leukemia trials registered on clinicaltrials.gov between 2010-2019.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:20.713706+00:00"}
{"study_id": 102542, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to compare the efficacy of a locally-produced HTK solution (containing Alanine) with the commercially available Custodiol HTK solution in adult liver transplantation candidates.", "results_summary": "The study found no statistically significant difference between the locally-produced HTK solution and Custodiol HTK in terms of efficacy for liver transplantation, suggesting comparable performance.", "population_specificity": "Adult patients undergoing liver transplantation.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:21.603232+00:00"}
{"study_id": 102545, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to examine the effect of hepatic steatosis (HS) on Asian patients with chronic hepatitis B (CHB), including its impact on antiviral therapy response and disease prognosis.", "results_summary": "The study found that HS prevalence in Asian CHB patients was 36.5%, negatively associated with antiviral therapy response (HBeAg seroconversion and ALT normalization) and potentially exacerbating hepatocellular carcinoma (HCC) progression. No significant association was observed between HS and fibrosis or cirrhosis in CHB patients.", "population_specificity": "Asian patients with chronic hepatitis B (CHB) and hepatic steatosis (HS).", "effective_dosage": "Not specified", "study_duration": "48 weeks of treatment", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:25.598791+00:00"}
{"study_id": 102543, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate the prognostic role of the elevated AST/ALT ratio (including alanine aminotransferase) in predicting major adverse cardio-cerebral events (MACCE) in patients with unstable angina undergoing percutaneous coronary intervention.", "results_summary": "The study found that a higher AST/ALT ratio was associated with increased risk of MACCE, particularly target vessel revascularization, with an optimal cutoff ratio of 1.29 demonstrating moderate predictive accuracy (sensitivity 77.5%, specificity 65.1%). Multivariate analysis confirmed the AST/ALT ratio as an independent predictor of MACCE.", "population_specificity": "1123 patients with unstable angina (mean age 62.3 years; 54.5% male) undergoing percutaneous coronary intervention.", "effective_dosage": "Not specified", "study_duration": "13 months of follow-up", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:25.997734+00:00"}
{"study_id": 102548, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to investigate the prevalence of delirium and its risk factors, including higher aspartic transaminase/alanine transaminase ratio, in hospitalized COVID-19 patients.", "results_summary": "The study found that a higher aspartic transaminase/alanine transaminase ratio was a significant risk factor for delirium in COVID-19 patients (OR = 1.11, p = 0.018). However, the abstract does not provide specific results about alanine's effects beyond this association.", "population_specificity": "Hospitalized COVID-19 patients at seven tertiary hospitals.", "effective_dosage": "Not available", "study_duration": "Not available", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:26.412305+00:00"}
{"study_id": 102544, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the anti-HBV efficacy, safety, and perinatal transmission outcomes of various ART regimens in pregnant women co-infected with HIV and HBV, including monitoring alanine aminotransferase (ALT) levels as a safety measure.", "results_summary": "The study found that HBV-active ART regimens led to significant HBV viral load suppression, with no major differences between single or dual anti-HBV agents. ALT/AST elevations (grade 3 or 4) were rare, occurring in 2.4-6.3% of participants across groups.", "population_specificity": "Pregnant women co-infected with HIV and HBV at 14 or more weeks of gestation.", "effective_dosage": "Not specified for alanine (ALT was monitored, not administered).", "study_duration": "Antepartum period (from enrollment at median 27 weeks gestation to delivery).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:26.535061+00:00"}
{"study_id": 102549, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the effects of vitamin E supplementation on alanine aminotransferase (ALT) and other liver health markers in patients with nonalcoholic fatty liver disease (NAFLD).", "results_summary": "Vitamin E supplementation significantly reduced ALT, AST, fibrosis, and steatosis in NAFLD patients but had no effect on GGT. Higher dosages (>600 IU/day) and longer treatment durations (\u226512 months) notably improved fibrosis scores.", "population_specificity": "Patients with nonalcoholic fatty liver disease (NAFLD).", "effective_dosage": ">600 IU/day for fibrosis improvement.", "study_duration": "\u226512 months for fibrosis improvement.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:27.581777+00:00"}
{"study_id": 102550, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers sought to identify determinants of sustained stabilization of beta-cell function in early type 2 diabetes patients following short-term insulin therapy and metformin maintenance, with a focus on changes in hepatic insulin resistance and alanine aminotransferase.", "results_summary": "The study found that sustained stabilization of beta-cell function was associated with initial reversibility of beta-cell dysfunction during insulin induction and preservation of hepatic insulin sensitivity during metformin maintenance, with changes in alanine aminotransferase also playing a role.", "population_specificity": "Adults with \u22645-years duration of type 2 diabetes.", "effective_dosage": "Not specified for alanine.", "study_duration": "2 years (including 3-week induction and intermittent 2-week insulin courses every 3 months).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:30.000079+00:00"}
{"study_id": 102551, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to compare the efficacy and safety of camrelizumab plus rivoceranib versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma, not specifically focused on Alanine.", "results_summary": "The study found that camrelizumab plus rivoceranib significantly improved progression-free survival and overall survival compared to sorafenib in patients with unresectable hepatocellular carcinoma. Increased alanine aminotransferase was noted as a common grade 3 or 4 treatment-related adverse event in the camrelizumab-rivoceranib group.", "population_specificity": "Patients with unresectable or metastatic hepatocellular carcinoma who had not previously received any systemic treatment.", "effective_dosage": "Not specified for Alanine.", "study_duration": "Median follow-up was 14.5 months for overall survival analysis.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:30.738462+00:00"}
{"study_id": 102552, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to assess the safety, tolerability, and efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with relapsed or refractory follicular lymphoma.", "results_summary": "The study found that the combination therapy did not result in unexpected safety events, with an objective response rate of 76.9% (17 complete responses and 3 partial responses). Common adverse events included pyrexia, neutropenia, and diarrhea, with 30.8% of patients discontinuing treatment due to adverse events.", "population_specificity": "Patients \u226518 years with histologically confirmed CD20-positive follicular lymphoma, relapsed or refractory to prior rituximab-containing regimens.", "effective_dosage": "Parsaclisib 20 mg once daily for 8 weeks, followed by 20 mg once weekly thereafter.", "study_duration": "Not explicitly stated in the abstract.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:32.271431+00:00"}
{"study_id": 102553, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the role of the Alanine, aspartate, and glutamate metabolism pathway in improving cognitive function in methamphetamine-dependent individuals through aerobic exercise.", "results_summary": "The study found that aerobic exercise significantly increased the Alanine, aspartate, and glutamate metabolism pathway in MA-dependent individuals, correlating with improved cognitive function. The modulation of gut microbiota and associated metabolic pathways, including Alanine metabolism, played a role in these cognitive improvements.", "population_specificity": "Methamphetamine-dependent individuals (n=64, split into aerobic exercise and conventional rehabilitation groups).", "effective_dosage": "Not specified", "study_duration": "8 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:33.924553+00:00"}
{"study_id": 102557, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to investigate the association between fasting plasma liver-expressed antimicrobial peptide 2 (FP-LEAP2) and markers of cardiometabolic disease susceptibility in individuals with prediabetes and overweight/obesity, and whether antidiabetic interventions affect FP-LEAP2 levels.", "results_summary": "The abstract does not provide specific results regarding Alanine's effects.", "population_specificity": "115 individuals with prediabetes (HbA1c 5.7%-6.4%) and overweight/obesity (BMI \u2265 25 kg/m\u00b2).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:34.276651+00:00"}
{"study_id": 102554, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to review the effect of tofogliflozin on hepatic outcomes, including alanine transaminase (ALT) levels, in type 2 diabetes mellitus (T2DM) patients.", "results_summary": "Tofogliflozin significantly decreased ALT levels in T2DM patients, along with other hepatic parameters like AST, GGT, ALP, and MRI-PDFF, but no significant change in adiponectin levels was observed.", "population_specificity": "T2DM patients with concurrent liver disorders.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:34.434948+00:00"}
{"study_id": 102558, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were evaluating the activity and safety of pembrolizumab in rare and ultra-rare sarcomas, not specifically studying Alanine.", "results_summary": "The study reported an objective response rate of 6.2% at week 12 with pembrolizumab in rare sarcomas, with manageable toxicity, including alanine aminotransferase increase as a common adverse event. Alanine itself was not the focus of the study.", "population_specificity": "Patients with rare and ultra-rare sarcomas (incidence <1 per 1,000,000 people/year).", "effective_dosage": "Pembrolizumab 200 mg intravenously every 21 days.", "study_duration": "Up to 24 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:36.086503+00:00"}
{"study_id": 102561, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the effects of zinc supplementation on cardiovascular disease risk factors, including Alanine aminotransferase (ALT).", "results_summary": "The study found no noticeable effects of zinc supplementation on Alanine aminotransferase (ALT) levels.", "population_specificity": "Not specified (general population with cardiovascular disease risk factors).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:37.404985+00:00"}
{"study_id": 102556, "supplement_id": 863, "safety_score": "85", "efficacy_score": 75, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the efficacy and safety of JNJ-73763989 (JNJ-3989) and JNJ-56136379 (JNJ-6379) in combination with nucleos(t)ide analogues for treating chronic hepatitis B, including their impact on alanine aminotransferase levels and other HBV markers.", "results_summary": "The study found that JNJ-3989 led to a dose-dependent response in meeting nucleos(t)ide analogue-stopping criteria, with higher doses showing better efficacy. However, HBsAg seroclearance was rare, though most patients had clinically meaningful reductions in HBsAg.", "population_specificity": "Patients aged 18-65 years with chronic hepatitis B (HBsAg positive, including virologically suppressed, HBeAg positive, and HBeAg negative individuals).", "effective_dosage": "JNJ-3989 at 40 mg, 100 mg, or 200 mg every 4 weeks; JNJ-6379 at 250 mg daily.", "study_duration": "48 weeks of treatment followed by a follow-up phase.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:37.640545+00:00"}
{"study_id": 102563, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to investigate the efficacy and safety of statins in reducing liver biochemical indicators, including alanine aminotransferase levels, in patients with nonalcoholic fatty liver disease (NAFLD).", "results_summary": "The study found that statins significantly reduced alanine aminotransferase levels in NAFLD patients, along with improvements in other liver enzymes and lipid profiles, demonstrating a 17% higher total effective rate compared to the control group.", "population_specificity": "Patients with nonalcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:41.724686+00:00"}
{"study_id": 102566, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study did not evaluate Alanine's safety, efficacy, or quality; it focused on pembrolizumab and cabozantinib for metastatic renal cell carcinoma.", "results_summary": "The study did not report any findings related to Alanine.", "population_specificity": "Patients with metastatic renal cell carcinoma (clear-cell or non-clear cell histology).", "effective_dosage": "Not applicable", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:42.911887+00:00"}
{"study_id": 102565, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to evaluate the efficacy and safety of 4 mg saroglitazar treatment in patients with NAFLD or NASH, focusing on changes in serum alanine transaminase (ALT) levels and other liver and metabolic parameters.", "results_summary": "The study found that adjunct saroglitazar treatment significantly reduced ALT levels, improved liver stiffness, and enhanced metabolic parameters (serum glucose and lipid profile) in patients with NAFLD or NASH. The results were statistically significant, with a mean ALT reduction of 26.01 U/L.", "population_specificity": "Patients with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH).", "effective_dosage": "4 mg saroglitazar (frequency not specified).", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:44.486170+00:00"}
{"study_id": 102568, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to describe the clinical and genetic features of childhood-onset CPS1D, including the role of elevated blood alanine levels in diagnosis.", "results_summary": "The study found elevated blood alanine levels (757.06 \u00b5mol/L) in a patient with CPS1D, which contributed to the diagnosis alongside genetic testing. The findings highlight the importance of metabolic screening in atypical cases of CPS1D.", "population_specificity": "A single adolescent patient with childhood-onset CPS1D.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:45.098801+00:00"}
{"study_id": 102564, "supplement_id": 863, "safety_score": "90", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the efficacy and safety of seladelpar, a PPAR-\u03b4 agonist, in patients with primary biliary cholangitis who had an inadequate response or intolerance to UDCA.", "results_summary": "Seladelpar significantly improved liver biochemistry and reduced pruritus, with the 10 mg dose showing the most pronounced effects. Alanine aminotransferase levels decreased significantly with seladelpar compared to placebo, and no serious treatment-related adverse events were reported.", "population_specificity": "Patients with primary biliary cholangitis and inadequate response or intolerance to UDCA.", "effective_dosage": "5 mg and 10 mg daily.", "study_duration": "12 months (primary endpoint), though the study was amended to month 3 due to early termination.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:45.104057+00:00"}
{"study_id": 102562, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the efficacy and safety of bepirovirsen in reducing hepatitis B surface antigen (HBsAg) and HBV DNA levels in participants with chronic HBV infection, both with and without background nucleos(t)ide analogue therapy.", "results_summary": "The study demonstrated that bepirovirsen induced rapid and prolonged HBsAg reduction with a favorable safety profile. The primary endpoint was HBsAg and HBV DNA seroclearance for 24 weeks post-treatment, assessed in a large, randomized cohort.", "population_specificity": "Participants with chronic HBV infection, either receiving stable nucleos(t)ide analogue therapy (On-NA) or not currently on NA therapy (Not-on-NA), with specific HBsAg, HBV DNA, and alanine aminotransferase thresholds.", "effective_dosage": "300 mg weekly (with 300 mg loading doses on days 4 and 11) for 24 weeks; 300 mg for 12 weeks followed by 150 mg for 12 weeks; 300 mg for 12 weeks followed by placebo for 12 weeks; placebo for 12 weeks followed by 300 mg for 12 weeks.", "study_duration": "24 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:45.724452+00:00"}
{"study_id": 102567, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to establish consensus on treatment endpoints for chronic HBV and HDV, including the role of alanine aminotransferase normalization as an alternate endpoint in trials.", "results_summary": "The study defined \"partial cure\" for HBV and alternate endpoints for HDV, including normalization of alanine aminotransferase levels combined with HDV RNA reduction, but did not specifically evaluate alanine's effects.", "population_specificity": "Patients with chronic hepatitis B (HBeAg positive or negative, treatment-naive or virally suppressed) and chronic hepatitis D (treatment-naive or experienced with quantifiable HDV RNA).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:45.806064+00:00"}
{"study_id": 102569, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the safety, tolerability, and pharmacokinetics of ecnoglutide, a novel GLP-1 analog with an alanine substitution, in healthy participants.", "results_summary": "Ecnoglutide demonstrated potent in vitro and in vivo activity, improved glycemic control and weight loss in animal models, and showed favorable pharmacokinetics and tolerability in human trials.", "population_specificity": "Healthy participants (Phase 1 study) and db/db mice/DIO rats (preclinical).", "effective_dosage": "SAD doses ranged from 0.03 to 1.0 mg; MAD doses ranged from 0.2 to 0.6 mg once weekly.", "study_duration": "6 weeks for MAD.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:51.477503+00:00"}
{"study_id": 102570, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to investigate the association between PCOS phenotypes and insulin resistance, including correlations with alanine transaminase levels.", "results_summary": "The study found a positive correlation between HOMA-IR (insulin resistance) and alanine transaminase levels in normal-weight PCOS women, but did not assess alanine's direct effects or supplementation.", "population_specificity": "Women aged 18-40 diagnosed with PCOS (n=125), categorized by BMI (normal weight and overweight/obese) and Rotterdam PCOS phenotypes.", "effective_dosage": "Not available", "study_duration": "Not specified (cross-sectional analysis of baseline RCT data)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:52.061275+00:00"}
{"study_id": 102573, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the causal relationship between NAFLD and changes in sleep traits, including associations with alanine transaminase levels.", "results_summary": "The study found significant associations between insomnia and elevated alanine transaminase levels (OR=2.79, P=4.71\u00d710-5) and between snoring and increased alanine transaminase levels (OR=1.27, P=0.04).", "population_specificity": "Individuals with NAFLD and sleep-related traits, based on genetic data from GWAS databases.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:53.157997+00:00"}
{"study_id": 102574, "supplement_id": 863, "safety_score": "90", "efficacy_score": 85, "quality_score": 88, "study_goal": "The researchers aimed to investigate the effects of Chios Mastiha Essential Oil (CMEO) on metabolic abnormalities, including its impact on alanine aminotransferase levels in individuals with abdominal obesity and metabolic disorders.", "results_summary": "The study found that CMEO significantly decreased alanine aminotransferase levels (p = 0.022) and improved lipid profiles, blood pressure, and body composition, with no reported adverse effects.", "population_specificity": "Individuals with abdominal obesity and metabolic abnormalities (dyslipidemia, hypertension, insulin resistance).", "effective_dosage": "200 mg of CMEO daily.", "study_duration": "3 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:53.970730+00:00"}
{"study_id": 102571, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the efficacy of bulevirtide in reducing HDV RNA and ALT levels in patients with chronic hepatitis D.", "results_summary": "Bulevirtide treatment at 2 mg and 10 mg doses significantly reduced HDV RNA levels and normalized ALT levels compared to the control group, with higher doses showing slightly better efficacy. The primary end-point response was achieved in 45% and 48% of patients in the 2-mg and 10-mg groups, respectively, versus 2% in the control group.", "population_specificity": "Patients with chronic hepatitis D, with or without compensated cirrhosis.", "effective_dosage": "2 mg per day or 10 mg per day, administered subcutaneously.", "study_duration": "144 weeks for treatment groups, 48 weeks for the control group followed by 96 weeks of treatment.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:54.134547+00:00"}
{"study_id": 102575, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers investigated whether pre-infection metabolic dysregulation, including elevated alanine aminotransferase (ALT), was associated with severe COVID-19 outcomes in patients under 65 years of age.", "results_summary": "Elevated ALT (>40) was associated with a 1.74-fold increased risk of severe COVID-19 outcomes (hospitalization or death). The study did not assess Alanine as a supplement but rather as a biomarker of metabolic dysfunction.", "population_specificity": "Patients under 65 years of age with confirmed COVID-19 (n=3870).", "effective_dosage": "Not applicable (ALT was measured as a biomarker, not administered).", "study_duration": "Observational period from March 1 to December 18, 2020.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:55.206297+00:00"}
{"study_id": 102572, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to compare the effectiveness of daily and weekly glucagon-like peptide-1 receptor agonists (GLP-1RAs) on liver fat content (LFC), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) levels in patients with NAFLD and T2DM.", "results_summary": "The study found that daily GLP-1RAs, particularly semaglutide (qd), were more effective in improving AST and ALT levels compared to weekly treatments. Exenatide (bid) was the best for reducing LFC, while semaglutide (qd) showed the highest efficacy for AST and ALT outcomes.", "population_specificity": "Patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM).", "effective_dosage": "Not specified for alanine aminotransferase (ALT) specifically; interventions included various GLP-1RAs (e.g., exenatide bid, semaglutide qd/qw).", "study_duration": "Not explicitly stated in the abstract.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:56.188178+00:00"}
{"study_id": 102576, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to summarize the preparation methods, structure-effect relationships, and effectiveness of DPP-IV and \u03b1-glucosidase inhibitory peptides, including those containing alanine, for treating type 2 diabetes.", "results_summary": "The study found that \u03b1-glucosidase inhibitory peptides containing alanine at the C-terminal are highly active, suggesting potential efficacy in diabetes treatment. The review also highlighted the importance of specific amino acid sequences in peptide activity.", "population_specificity": "Not specified (review of cellular and animal models).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:59.906815+00:00"}
{"study_id": 102577, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to develop and validate a prognostic model to predict 6-month mortality in patients with drug-induced liver injury (DILI), using alanine aminotransferase as one of the predictive parameters.", "results_summary": "The study developed a DILI mortality predictive (DMP) score incorporating alanine aminotransferase among other laboratory parameters, which accurately predicted 6-month mortality in DILI patients across multiple cohorts.", "population_specificity": "Patients admitted to three hospitals with drug-induced liver injury (DILI).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:00.542267+00:00"}
{"study_id": 102578, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine whether early gastroenterology/hepatology consultation improved the management of severe immune checkpoint inhibitor-induced hepatitis, particularly focusing on alanine aminotransferase (ALT) normalization and improvement.", "results_summary": "Early consultation was not associated with faster ALT normalization in steroid-responsive hepatitis but was linked to faster ALT normalization and improvement in steroid-refractory hepatitis, primarily due to earlier initiation of additional immunosuppressive therapy.", "population_specificity": "294 patients with grade \u22653 ICI-induced hepatitis (ALT >200 U/L).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:01.340588+00:00"}
{"study_id": 102579, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to summarize current knowledge on miRNA-based approaches, including miRNA-34a antagonist/inhibitor, for treating NAFLD/NASH.", "results_summary": "The study identified 56 miRNAs as potential therapeutic agents, with miRNA-34a antagonist/inhibitor being the most studied variant. The abstract does not mention specific results related to Alanine.", "population_specificity": "Not specified (focus on NAFLD/NASH patients, but no demographic details provided).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:01.342037+00:00"}
{"study_id": 102581, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the effect of plant-based n-3 fatty acid supplementation on NAFLD surrogate biomarkers, including alanine aminotransferase (ALT).", "results_summary": "Plant-based n-3 supplementation significantly reduced ALT levels and plasma/serum triglycerides, alongside improvements in body-composition markers in NAFLD patients. The effects were statistically significant (P < 0.05).", "population_specificity": "Patients diagnosed with nonalcoholic fatty liver disease (NAFLD) (n = 362).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:02.760683+00:00"}
{"study_id": 102580, "supplement_id": 863, "safety_score": "65", "efficacy_score": 50, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety and efficacy of INCB053914, a pan-PIM kinase inhibitor, as monotherapy or in combination with standard-of-care agents for advanced hematologic malignancies, with a focus on adverse events including ALT/AST elevation.", "results_summary": "The study found that INCB053914 was generally well tolerated, with elevated ALT/AST being the most common adverse event. Limited therapeutic responses were observed in combination therapies, with two complete responses in AML patients and modest spleen volume reduction in MF patients.", "population_specificity": "Adults (\u226518 years) with advanced hematologic malignancies, including acute leukemia, MDS, MF, multiple myeloma, and lymphoproliferative neoplasms.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:03.592240+00:00"}
{"study_id": 102582, "supplement_id": 863, "safety_score": "85", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the feasibility, safety, and efficacy of bulevirtide in patients with HBV/HDV-related cirrhosis and clinically significant portal hypertension, including those with HIV co-infection.", "results_summary": "The study found that bulevirtide was well-tolerated, with no discontinuations due to adverse effects, and led to significant reductions in ALT levels, liver/spleen stiffness, and HDV-RNA, with similar efficacy in patients with and without HIV.", "population_specificity": "Patients with HBV/HDV-related cirrhosis and clinically significant portal hypertension, including those living with HIV (61.5% migrants).", "effective_dosage": "Not specified", "study_duration": "Median treatment duration was 11 months.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:04.854130+00:00"}
{"study_id": 102583, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to compare the efficacy and safety of eribulin monotherapy versus eribulin plus anlotinib in patients with HER2-negative, locally recurrent or metastatic breast cancer, not specifically focused on Alanine.", "results_summary": "The study reported elevated alanine aminotransferase levels as a common adverse event in both treatment groups (62.5% in monotherapy vs. 75.0% in combination therapy), but did not evaluate Alanine's efficacy or primary effects.", "population_specificity": "Patients with HER2-negative, locally recurrent or metastatic breast cancer previously treated with anthracycline- or taxane-based chemotherapy.", "effective_dosage": "Not specified for Alanine.", "study_duration": "Not specified for Alanine.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:08.603099+00:00"}
{"study_id": 102584, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study aimed to assess the efficacy and toxicity of ruxolitinib in treating steroid-refractory graft-versus-host disease (SR-GVHD) in children, not Alanine.", "results_summary": "The study found ruxolitinib had an overall response rate of 64.3% in pediatric SR-GVHD patients, with adverse effects observed in 64.3% of cases, including elevated alanine aminotransferase.", "population_specificity": "Pediatric patients (ages 3 months to 12 years) with SR-GVHD after allogeneic hematopoietic stem cell transplantation.", "effective_dosage": "2.5 mg to 7.5 mg twice daily, based on patient weight.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:10.316471+00:00"}
{"study_id": 102586, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study evaluated the efficacy and safety of tazobactam/ceftolozane (TAZ/CTLZ) in combination with metronidazole for intraabdominal infections, not specifically Alanine.", "results_summary": "The study reported increased alanine aminotransferase activities in 6.0% of patients, which improved after discontinuation of the antibiotic. No direct effects or outcomes related to Alanine supplementation were assessed.", "population_specificity": "50 patients with intraabdominal infections in the hepato-biliary-pancreatic field.", "effective_dosage": "Not mentioned (study focused on antibiotic combination, not Alanine).", "study_duration": "Not specified (study duration not detailed in the abstract).", "interactions": "None mentioned (study did not assess Alanine interactions).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:11.152297+00:00"}
{"study_id": 102560, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the prognostic value of the aspartate aminotransferase-to-alanine aminotransferase ratio (De Ritis ratio) in predicting overall survival (OS) and disease-free survival (DFS) in stage II/III colorectal cancer (CRC) patients.", "results_summary": "The De Ritis ratio was identified as an independent predictor for both OS and DFS in stage II/III CRC patients. Nomograms incorporating this ratio and clinicopathological features showed improved accuracy and clinical utility compared to traditional staging systems.", "population_specificity": "4014 stage II/III primary CRC patients diagnosed between 2007 and 2013.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:11.420875+00:00"}
{"study_id": 102585, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 90, "study_goal": "The researchers investigated the association of liver markers, including alanine aminotransferase (ALT), with heart failure outcomes and the treatment effect of empagliflozin in patients with HFpEF.", "results_summary": "High ALT was associated with better outcomes for heart failure hospitalization or cardiovascular death, while empagliflozin had no significant effect on ALT levels. The treatment benefits of empagliflozin were not influenced by baseline liver parameters.", "population_specificity": "5988 patients with heart failure with preserved ejection fraction (HFpEF), excluding those with significant liver disease.", "effective_dosage": "Not specified for alanine (study focused on empagliflozin 10 mg daily).", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:11.845749+00:00"}
{"study_id": 102589, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to determine whether whey protein supplementation (WPS) enhances the effects of resistance exercise on hepatic fat content (HFC) and lipid profiles.", "results_summary": "WPS did not significantly enhance the overall effects of resistance exercise on HFC and lipid profiles but may have a partial beneficial effect on liver enzymatic changes and rapid response to HFC reduction.", "population_specificity": "34 sedentary males", "effective_dosage": "Not specified", "study_duration": "4 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:13.532428+00:00"}
{"study_id": 102587, "supplement_id": 863, "safety_score": "70", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the efficacy and safety of vorasidenib, an inhibitor of mutant IDH enzymes, in patients with grade 2 IDH-mutant glioma, with a focus on progression-free survival and time to next intervention.", "results_summary": "Vorasidenib significantly improved progression-free survival (27.7 months vs. 11.1 months) and delayed the time to the next intervention compared to placebo. However, it was associated with a higher incidence of grade 3 or higher adverse events, including elevated alanine aminotransferase levels (9.6% vs. 0%).", "population_specificity": "Patients with residual or recurrent grade 2 IDH-mutant glioma who had undergone no previous treatment other than surgery.", "effective_dosage": "40 mg once daily in 28-day cycles.", "study_duration": "Median follow-up of 14.2 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:13.549701+00:00"}
{"study_id": 102588, "supplement_id": 863, "safety_score": "75", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to study the pharmacokinetic drug-drug interactions of HP501, febuxostat, and colchicine in hyperuricemic patients, focusing on safety and efficacy.", "results_summary": "Coadministration of HP501, febuxostat, and colchicine did not produce clinically meaningful drug interactions. HP501 alone reduced serum uric acid (sUA) by 24.77%, while combined with febuxostat, it achieved a 55.82% reduction, with all patients reaching sUA < 360 \u03bcmol/L. Adverse events were mild or moderate, primarily diarrhea and elevated ALT levels.", "population_specificity": "Hyperuricemic patients", "effective_dosage": "HP501 40 mg once daily; febuxostat 40 mg once daily; colchicine 0.5 mg once daily", "study_duration": "7-12 days", "interactions": "No significant pharmacokinetic interactions between HP501, febuxostat, and colchicine.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:15.158257+00:00"}
{"study_id": 102590, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the effects of the Mediterranean diet on markers such as alanine aminotransferase (ALT) in patients with non-alcoholic fatty liver disease (NAFLD).", "results_summary": "The study found that the Mediterranean diet may reduce liver stiffness, though the effect on ALT was not explicitly detailed in the abstract. The overall impact on liver enzymes and fibrosis markers appeared modest.", "population_specificity": "Adults with non-alcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified (dietary intervention).", "study_duration": "6 weeks to 1 year.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:16.128729+00:00"}
{"study_id": 102591, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to determine whether blood levels of alanine phosphatase (ALP) and gamma-glutamyl-transferase (GGT) could predict survival in metastatic pancreatic cancer patients.", "results_summary": "Patients with low GGT levels lived longer, while those with liver metastasis and high ALP/GGT levels had worse prognoses. Higher ALP and GGT levels were associated with poor outcomes in patients receiving nab-paclitaxel/gemcitabine treatment.", "population_specificity": "153 patients with metastatic pancreatic cancer receiving first-line treatment.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:17.998802+00:00"}
{"study_id": 102593, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers were evaluating the efficacy and safety of immune checkpoint inhibitors (IN) in melanoma patients with brain metastases (MBM), not specifically studying Alanine.", "results_summary": "The abstract does not discuss Alanine's effects; it focuses on immune checkpoint inhibitors' outcomes in MBM patients.", "population_specificity": "Melanoma patients with brain metastases (MBM).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:18.466741+00:00"}
{"study_id": 102592, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to evaluate the effect of SGLT-2 inhibitors on NAFLD patients' outcomes, including changes in liver enzymes like alanine transaminase (ALT).", "results_summary": "SGLT-2 inhibitors showed positive effects on liver enzymes (ALT, AST, GGT), lipid profiles (HDL, TG, LDL), and BMI in NAFLD patients, with statistically significant improvements reported in multiple trials.", "population_specificity": "NAFLD patients, with or without type 2 diabetes (T2DM).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:18.696996+00:00"}
{"study_id": 102594, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to describe the demographic and clinical characteristics of patients with Lysosomal Acid Lipase Deficiency (LAL-D), focusing on common manifestations such as elevated alanine aminotransferase levels.", "results_summary": "Elevated alanine aminotransferase levels were a common manifestation (70%) raising suspicion of LAL-D, but the study did not evaluate alanine's efficacy or safety as a supplement.", "population_specificity": "Patients diagnosed with LAL-D, including children (\u22656 months to <18 years) and adults.", "effective_dosage": "Not available", "study_duration": "Not applicable (observational study)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:20.613710+00:00"}
{"study_id": 102595, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 65, "study_goal": "The researchers aimed to determine the effectiveness of herbal medicines, including those affecting alanine aminotransferase (ALT), on cirrhosis.", "results_summary": "Three of six studies showed beneficial effects of silymarin on ALT levels in cirrhosis patients, but the abstract does not specifically isolate alanine's role.", "population_specificity": "Patients with cirrhosis (613 patients in silymarin studies, 118 in curcumin studies, 4 in ginseng studies).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:20.705129+00:00"}
{"study_id": 102596, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to systematically summarize the effects of chicory (not Alanine) on liver function and lipid profile in patients with NAFLD.", "results_summary": "Chicory significantly decreased aspartate transaminase and alanine transaminase levels but had no significant effects on alkaline phosphatase, gamma-glutamyl transferase, or lipid profile components.", "population_specificity": "Patients with non-alcoholic fatty liver disease (NAFLD)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:21.361363+00:00"}
{"study_id": 102599, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to determine the effect of turmeric/curcumin supplementation on liver function tests, including alanine aminotransferase (ALT).", "results_summary": "Turmeric/curcumin supplementation significantly reduced ALT levels (WMD = -4.09 U/L), though the clinical relevance remains uncertain. No significant effect was observed on GGT levels.", "population_specificity": "Participants in randomized controlled trials (RCTs) examining liver function.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:23.153369+00:00"}
{"study_id": 102598, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 85, "study_goal": "The researchers examined the impact of ursodeoxycholic acid (UDCA) on liver enzymes, HbA1c, lipids, and inflammation markers in patients after bariatric surgery, not specifically Alanine.", "results_summary": "UDCA led to a clinically insignificant increase in alkaline phosphatase (ALP) but no significant changes in other liver enzymes, HbA1c, lipids, or CRP levels. Postoperative comparisons showed higher total cholesterol and lower aspartate and alanine aminotransferase levels in the UDCA group.", "population_specificity": "Patients who underwent bariatric surgery (mean age 45.6 \u00b1 10.7 years, 79% female).", "effective_dosage": "900 mg daily", "study_duration": "6 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:23.636399+00:00"}
{"study_id": 102600, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effects of postoperative hyperthermic intraperitoneal chemotherapy (HIPEC) on serum electrolytes, including alanine aminotransferase, in patients who underwent open radical gastrectomy.", "results_summary": "The study found statistical differences in alanine aminotransferase levels between the HIPEC and control groups, though the clinical significance of these changes requires further exploration. HIPEC did not significantly affect liver function but may have impacted renal function and electrolyte balance.", "population_specificity": "153 patients who underwent open radical gastrectomy (83 in the HIPEC group, 70 in the control group).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:26.220652+00:00"}
{"study_id": 102604, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study did not assess Alanine; it focused on evaluating tucatinib plus trastuzumab for HER2-positive metastatic colorectal cancer.", "results_summary": "The study did not report findings related to Alanine.", "population_specificity": "Patients with chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer.", "effective_dosage": "Not applicable", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:27.158154+00:00"}
{"study_id": 102601, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to identify potential mechanisms of SARS-CoV-2-induced liver damage, including the role of Alanine aminotransferase abnormalities, and explore treatment outcomes in infected patients.", "results_summary": "The study found that liver damage in COVID-19 patients includes elevated Alanine aminotransferase levels and histopathological changes, but it did not assess Alanine's direct effects or therapeutic use.", "population_specificity": "SARS-CoV-2-infected patients with liver damage.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:29.158677+00:00"}
{"study_id": 102605, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The study does not focus on Alanine but rather investigates metabolic bone disease (hepatic osteodystrophy) and thyroid dysfunction in liver cirrhosis patients.", "results_summary": "The study found vitamin D deficiency, raised PTH, and low urinary calcium in a patient with liver disease, leading to a diagnosis of osteomalacia. It also noted lower FT3 and FT4 levels and higher TSH levels in cirrhosis patients, correlating with disease severity.", "population_specificity": "Patients with liver cirrhosis and metabolic bone disease.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:31.558612+00:00"}
{"study_id": 102602, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 85, "study_goal": "The researchers aimed to assess the safety and efficacy of tropifexor (TXR) and cenicriviroc (CVC) combination therapy, including its impact on alanine aminotransferase (ALT) levels, compared to monotherapies in patients with NASH.", "results_summary": "The study found that TXR monotherapy and combination therapies led to sustained decreases in ALT levels and body weight, but no substantial incremental efficacy was observed with the combination compared to monotherapy. Histological improvements were modest and similar across treatment groups.", "population_specificity": "Patients with NASH (N = 193).", "effective_dosage": "TXR 140 \u03bcg, TXR 90 \u03bcg, CVC 150 mg, or combinations (TXR 140 + CVC 150 mg, TXR 90 + CVC 150 mg), administered once daily.", "study_duration": "48 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:32.087013+00:00"}
{"study_id": 102603, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate whether prophylactic terlipressin reduces the occurrence of severe postreperfusion syndrome (PRS) in deceased donor liver transplantation, with secondary outcomes including effects on alanine transaminase levels.", "results_summary": "Prophylactic terlipressin significantly reduced severe PRS incidence (9.4% vs. 53.1%) and peak alanine transaminase levels post-transplantation, though it increased pulmonary capillary wedge pressure and prolonged mechanical ventilation time.", "population_specificity": "Adults undergoing deceased donor liver transplantation.", "effective_dosage": "1 mg of terlipressin immediately after portal vein clamping.", "study_duration": "Single dose administered perioperatively.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:32.087682+00:00"}
{"study_id": 102607, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the clinical efficacy of probiotics, including their impact on alanine aminotransferase (ALT) levels, in the treatment of patients with nonalcoholic fatty liver disease (NAFLD).", "results_summary": "Probiotic adjuvant therapy significantly improved liver function by reducing ALT, AST, and GGT levels, as well as improving lipid metabolism, blood glucose, insulin resistance, BMI, and inflammatory markers like TNF-\u03b1. The treatment effect was more pronounced when the intervention lasted over 12 weeks.", "population_specificity": "Patients with nonalcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Varied, with more pronounced effects observed when treatment exceeded 12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:32.614473+00:00"}
{"study_id": 102606, "supplement_id": 863, "safety_score": "75", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of MSB2311, a pH-dependent anti-PD-L1 monoclonal antibody, in patients with advanced solid tumors or lymphoma.", "results_summary": "MSB2311 showed manageable safety with common adverse events like anemia and elevated liver enzymes, and demonstrated promising antitumor activity, with a 30% objective response rate in biomarker-positive solid tumors and one partial response in lymphoma patients.", "population_specificity": "37 Chinese patients (31 with solid tumors, 6 with lymphoma) with advanced disease and specific biomarker profiles.", "effective_dosage": "3, 10, and 20 mg/kg every 3 weeks (Q3W) and 10 mg/kg every 2 weeks (Q2W).", "study_duration": "Administered every 2 or 3 weeks until dose-limiting toxicity or disease progression.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:32.649103+00:00"}
{"study_id": 102608, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine the therapeutic effect of ulinastatin (UTI) on unliquefied pyogenic liver abscesses complicated by septic shock (UPLA-SS), including its impact on liver function and inflammatory indices.", "results_summary": "UTI combined with conventional treatment significantly improved liver function, reduced inflammatory markers, and shortened treatment time in UPLA-SS patients compared to the control group, though mortality rates did not differ significantly.", "population_specificity": "Patients with unliquefied pyogenic liver abscesses complicated by septic shock (UPLA-SS).", "effective_dosage": "200,000 units q8h for >3 days.", "study_duration": ">3 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:34.915841+00:00"}
{"study_id": 102609, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to investigate the pharmacokinetics of rivaroxaban in real-world patients and identify covariates affecting its variability, including the influence of alanine aminotransferase.", "results_summary": "The study found significant interindividual variability in rivaroxaban pharmacokinetics, with covariates like alanine aminotransferase affecting clearance. The results may guide clinicians in adjusting therapeutic regimens.", "population_specificity": "20 real-world patients (50% men/50% women, mean age 53.1 years, mean body weight 81.7 kg).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:35.183256+00:00"}
{"study_id": 102610, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to develop a predictive nomogram for HBV-related hepatocellular carcinoma (HCC) survival, incorporating alanine aminotransferase levels as one of the independent variables.", "results_summary": "The study found that alanine aminotransferase levels were an independent predictive variable for overall survival in HBV-related HCC patients. The nomogram demonstrated good predictive performance for 1-, 2-, and 3-year survival rates.", "population_specificity": "2281 HCC patients with HBV-related diagnosis.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:37.984430+00:00"}
{"study_id": 102611, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to determine the safety and efficacy of combining mTOR inhibitor nab-sirolimus with nivolumab in patients with advanced sarcoma or tumors with mTOR pathway mutations.", "results_summary": "The study found that the combination was safe with no unexpected adverse events, but treatment outcomes were not improved by combining the drugs. Best responders were patients with specific genetic mutations.", "population_specificity": "Patients \u226518 years with advanced sarcoma or tumors with mTOR pathway mutations.", "effective_dosage": "3 mg/kg nivolumab every 3 weeks; nab-sirolimus at 56, 75, or 100 mg/m\u00b2.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:40.943418+00:00"}
{"study_id": 102613, "supplement_id": 863, "safety_score": "85", "efficacy_score": 60, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the efficacy and safety of pegbelfermin, a fibroblast growth factor 21 analog, in patients with NASH and stage 3 fibrosis over 48 weeks.", "results_summary": "Pegbelfermin showed modest improvements in hepatic fat reduction and liver fibrosis markers compared to placebo, but the primary endpoint (fibrosis score improvement without NASH worsening) was not statistically significant. The treatment was well-tolerated with no serious adverse events reported.", "population_specificity": "Patients with biopsy-confirmed NASH and stage 3 (bridging) fibrosis (N = 197).", "effective_dosage": "Weekly subcutaneous injections of 10, 20, or 40 mg pegbelfermin.", "study_duration": "48 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:41.055503+00:00"}
{"study_id": 102614, "supplement_id": 863, "safety_score": "65", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to explore the clinical features of adverse drug events (ADEs) associated with eltrombopag, including effects on alanine aminotransferase levels, across different age groups.", "results_summary": "The study observed signals of elevated alanine aminotransferase levels in all age groups, indicating potential liver-related adverse effects. For children, additional signals included urinary tract infection and back pain.", "population_specificity": "Patients of various age groups (0-17, 18-64, and \u226565 years) from pharmacovigilance databases and randomized clinical trials.", "effective_dosage": "Not specified", "study_duration": "Data collected from 2008 to 2022", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:41.981792+00:00"}
{"study_id": 102612, "supplement_id": 863, "safety_score": "70", "efficacy_score": 40, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the efficacy and safety of pegbelfermin, a polyethylene glycol-conjugated analog of human fibroblast growth factor 21, in patients with nonalcoholic steatohepatitis (NASH) and compensated cirrhosis.", "results_summary": "Pegbelfermin did not significantly improve fibrosis scores compared to placebo, though it showed some improvements in liver stiffness, steatosis, and inflammation markers. Serious adverse events were more frequent with pegbelfermin, but none were treatment-related.", "population_specificity": "Adults with biopsy-confirmed NASH and stage 4 fibrosis (compensated cirrhosis).", "effective_dosage": "10, 20, or 40 mg injected subcutaneously once weekly.", "study_duration": "48 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:42.280785+00:00"}
{"study_id": 102615, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 60, "quality_score": 80, "study_goal": "The researchers aimed to examine the impact of meal glycaemic load on postprandial plasma metabolome responses, including alanine levels, in overweight postmenopausal women with and without Metabolic Syndrome.", "results_summary": "The study found that postprandial alanine levels were higher following a low glycaemic load meal compared to a high glycaemic load meal in overweight women with Metabolic Syndrome, though meal glycaemic load had minimal overall impact on the metabolome.", "population_specificity": "Overweight postmenopausal women (Healthy: n=20; Metabolic Syndrome: n=20).", "effective_dosage": "Not specified (test meals contained 73g carbohydrate, 51% energy).", "study_duration": "Acute intervention (single meal).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:42.344049+00:00"}
{"study_id": 102617, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to identify potential biomarkers, including alanine metabolism, involved in the early molecular response to hypoxic-ischemic encephalopathy in newborns.", "results_summary": "The study found that alanine, aspartate, and glutamate metabolism pathways were involved in the early molecular response to hypoxic-ischemic encephalopathy, suggesting a role in the condition's pathophysiology. However, the abstract does not detail specific effects of alanine supplementation or direct therapeutic outcomes.", "population_specificity": "Newborns >36 weeks with hypoxic-ischemic encephalopathy or perinatal asphyxia.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:43.419622+00:00"}
{"study_id": 102616, "supplement_id": 863, "safety_score": "85", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the pharmacokinetics, safety, tolerability, and effects on aminotransferases (specifically ALT) of elafibranor in children with NASH.", "results_summary": "Elafibranor was well tolerated and rapidly absorbed, with a 37.4% relative reduction in mean ALT levels in the 120 mg group after 12 weeks, suggesting potential improvement in liver histology.", "population_specificity": "Children aged 8-17 years with nonalcoholic steatohepatitis (NASH).", "effective_dosage": "80 mg or 120 mg once daily.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:43.445210+00:00"}
{"study_id": 102618, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study aimed to evaluate the efficacy and safety of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) for advanced non-small cell lung cancer after PD-(L)1 inhibitor failure, not Alanine.", "results_summary": "The study found nab-paclitaxel improved the objective response rate (55.2%) and disease control rate (86.2%) with a median progression-free survival of 5.6 months and median overall survival of 11.9 months. Adverse events included leukopenia, neutropenia, and peripheral sensory neuropathy, but no findings related to Alanine were reported.", "population_specificity": "Patients with advanced non-small cell lung cancer (NSCLC) who had failed PD-(L)1 inhibitor therapy.", "effective_dosage": "100 mg/m\u00b2", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:50.337898+00:00"}
{"study_id": 102619, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study aimed to compare the efficacy and safety of bepotastine besilate versus levocetirizine in patients with chronic spontaneous urticaria, not specifically Alanine.", "results_summary": "The study found no significant difference in alanine transaminase levels between the two treatment groups from baseline to the 4th week. Alanine was not a primary focus of the study.", "population_specificity": "100 patients with chronic spontaneous urticaria (50 in each treatment group).", "effective_dosage": "Not mentioned for Alanine.", "study_duration": "4 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:54.673522+00:00"}
{"study_id": 102620, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the relationship between liver function and rhabdomyolysis (RM) in hemorrhagic trauma patients, specifically examining the role of alanine transferase (ALT) as a biomarker.", "results_summary": "The study found a significant positive correlation between RM biomarkers (CK and myoglobin) and liver biomarkers (AST, ALT, bilirubin), with intense RM associated with higher liver failure rates. Liver failure was more common in patients with intense RM and linked to renal replacement therapy and SOFA scores.", "population_specificity": "Severely injured hemorrhagic trauma patients transfused within 24 hours and admitted to ICU, excluding those with significant direct liver injury.", "effective_dosage": "Not available", "study_duration": "Not applicable (retrospective observational study)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:55.148871+00:00"}
{"study_id": 102623, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers were not studying alanine directly but reported its levels as part of monitoring patient recovery from DNM.", "results_summary": "The study noted that alanine transaminase levels returned to normal post-treatment, indicating liver function recovery, but did not evaluate alanine's therapeutic effects.", "population_specificity": "A 53-year-old male with DNM caused by S. constellatus.", "effective_dosage": "Not applicable", "study_duration": "4 weeks of antibiotic therapy", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:56.067413+00:00"}
{"study_id": 102621, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to study clinic-radiologic profiles, risk factors, complications, and outcomes of pediatric liver abscess and assess predictors for poor outcomes, including elevated alanine transaminase levels.", "results_summary": "Elevated alanine transaminase (ALT) levels were significantly associated with poor outcomes in pediatric liver abscess patients. The study did not focus on alanine as a supplement but rather as a biomarker for liver dysfunction.", "population_specificity": "Children under 12 years of age with ultrasonographically diagnosed liver abscess in a tertiary care hospital in India.", "effective_dosage": "Not applicable", "study_duration": "Retrospective study covering records from January 2019 to September 2019.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:56.906755+00:00"}
{"study_id": 102622, "supplement_id": 863, "safety_score": "65", "efficacy_score": 25, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety, tolerability, efficacy, and pharmacokinetics of BPI-9016M, a tyrosine kinase inhibitor targeting c-MET, in patients with c-MET overexpression or MET exon 14 skipping mutation in NSCLC.", "results_summary": "BPI-9016M showed a manageable safety profile but limited efficacy, with common adverse events including elevated ALT and AST. The objective response rate was low (2.6%), and disease control rate was modest (42.1%).", "population_specificity": "Patients with locally advanced or metastatic NSCLC harboring c-MET overexpression or MET exon 14 skipping mutation.", "effective_dosage": "300 mg QD, 450 mg QD, 600 mg QD (Part A); 400 mg BID (Part B).", "study_duration": "Not explicitly stated in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:57.767086+00:00"}
{"study_id": 102625, "supplement_id": 863, "safety_score": "70", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the efficacy and safety of fitusiran prophylaxis, which targets antithrombin, in reducing bleeding events in people with severe haemophilia A or B without inhibitors.", "results_summary": "Fitusiran prophylaxis significantly reduced the annualised bleeding rate compared to on-demand clotting factor concentrates, with 51% of participants experiencing no treated bleeds. The most common adverse event in the fitusiran group was increased alanine aminotransferase concentration, but no treatment-related thrombosis or deaths were reported.", "population_specificity": "Male participants aged at least 12 years with severe haemophilia A or B without inhibitors.", "effective_dosage": "80 mg subcutaneous fitusiran once per month.", "study_duration": "9 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:58.779813+00:00"}
{"study_id": 102624, "supplement_id": 863, "safety_score": "70", "efficacy_score": 90, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the efficacy and safety of fitusiran prophylaxis, which targets antithrombin, in reducing bleeding rates in individuals with haemophilia A or B with inhibitors.", "results_summary": "Fitusiran prophylaxis significantly reduced the annualized bleeding rate by 90.8% compared to on-demand bypassing agents, with 66% of participants experiencing zero treated bleeds. The most frequent adverse event was increased alanine aminotransferase in 32% of participants, and two cases of thromboembolic events were reported.", "population_specificity": "Men, boys, and young adults aged 12 years or older with severe haemophilia A or B with inhibitors.", "effective_dosage": "80 mg subcutaneous once-a-month.", "study_duration": "9 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:59.139392+00:00"}
{"study_id": 102627, "supplement_id": 863, "safety_score": "65", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety and tolerability of eganelisib (a PI3K\u03b3 inhibitor) as monotherapy and in combination with nivolumab, including its effects on alanine aminotransferase (ALT) levels in patients with solid tumors.", "results_summary": "The study found that eganelisib monotherapy and combination therapy led to increased ALT and AST levels, with grade \u22653 toxicities occurring in 18% and 10% of patients, respectively. Antitumor activity was observed in combination therapy, including in patients who had progressed on PD-1/PD-L1 inhibitors.", "population_specificity": "Patients with solid tumors.", "effective_dosage": "Monotherapy: 10-60 mg once daily; Combination therapy: 20-40 mg once daily with nivolumab.", "study_duration": "Not specified in the abstract.", "interactions": "Combination with nivolumab (a PD-1 inhibitor).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:03.747733+00:00"}
{"study_id": 102629, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to evaluate the real-world efficacy and safety of atezolizumab and bevacizumab (Atezo/Bev) for unresectable hepatocellular carcinoma (HCC), including the impact of alanine aminotransferase (ALT) levels on outcomes.", "results_summary": "Increased ALT levels were associated with significantly shorter overall survival (OS) and progression-free survival (PFS), with hazard ratios of 6.68 and 3.54, respectively. Proteinuria, however, was linked to longer OS.", "population_specificity": "268 patients with unresectable HCC treated with Atezo/Bev.", "effective_dosage": "Not specified", "study_duration": "Median OS was 462 days, and median PFS was 239 days.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:04.252725+00:00"}
{"study_id": 102630, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effectiveness of Fuzheng Huayu preparation (FZHY) plus tenofovir disoproxil fumarate (TDF) on hepatitis B, particularly focusing on liver function and fibrosis markers including alanine transaminase.", "results_summary": "The combination therapy significantly reduced levels of alanine transaminase and other liver fibrosis markers compared to TDF alone, with subgroup analyses showing improved albumin levels in chronic hepatitis B patients and benefits with longer treatment durations (>24 weeks).", "population_specificity": "Patients with hepatitis B, including chronic hepatitis B and hepatitis B-related cirrhosis.", "effective_dosage": "Not specified", "study_duration": "Varied, with subgroup analyses comparing \u226424 weeks and >24 weeks.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:05.488501+00:00"}
{"study_id": 102626, "supplement_id": 863, "safety_score": "85", "efficacy_score": null, "quality_score": 90, "study_goal": "The researchers aimed to determine the safety and pharmacokinetic profile of CAP256V2LS, a monoclonal antibody, alone and in combination with VRC07-523LS, in young HIV-negative women.", "results_summary": "The study found that CAP256V2LS, alone and in combination, was safe with no serious adverse events or dose-limiting toxicities, though mild to moderate side effects like headaches and transient lymphocytopenia were reported. Pharmacokinetics and neutralization activity were favorable, supporting further clinical assessment.", "population_specificity": "Young HIV-negative women aged 18-45 in Durban, South Africa.", "effective_dosage": "Intravenous (5 mg/kg, 10 mg/kg) and subcutaneous (5 mg/kg, 10 mg/kg, 20 mg/kg) administration.", "study_duration": "From July 13, 2020, to Jan 13, 2021 (6 months).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:06.063978+00:00"}
{"study_id": 102628, "supplement_id": 863, "safety_score": "80", "efficacy_score": 60, "quality_score": 75, "study_goal": "The researchers evaluated the safety and clinical activity of bintrafusp alfa, which includes a TGF-\u03b2 trap and a PD-L1 inhibitor, in patients with chemorefractory biliary tract cancers.", "results_summary": "The study found that 10.7% of patients achieved an objective response, with a median duration of response of 10.0 months. Grade \u22653 adverse events occurred in 26.4% of patients, including increased alanine aminotransferase (1.9%).", "population_specificity": "Adults with locally advanced or metastatic biliary tract cancer who were intolerant to or had failed first-line systemic platinum-based chemotherapy.", "effective_dosage": "1200 mg intravenously every 2 weeks.", "study_duration": "Median follow-up was 16.1 months (range, 0.0-19.3 months).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:06.196938+00:00"}
{"study_id": 102631, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to identify plasma biomarkers, including alanine transaminase, for early diagnosis of sepsis-associated liver dysfunction (SALD).", "results_summary": "The study analyzed alanine transaminase among other biomarkers but did not specifically report its efficacy or outcomes related to SALD prediction or survival.", "population_specificity": "79 patients with sepsis and septic shock treated in the ICU.", "effective_dosage": "Not available", "study_duration": "Plasma samples were obtained within 24 hours of sepsis/septic shock onset; patients were followed for 14 days for SALD development and 28 days for survival.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:08.058029+00:00"}
{"study_id": 102633, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 90, "quality_score": 75, "study_goal": "To evaluate the safety and efficacy of fixed-dose sofosbuvir/ledipasvir combination in kidney transplant recipients with hepatitis C virus infection.", "results_summary": "All patients achieved sustained virologic response (SVR12), with no graft failures or deaths reported. The treatment was effective and safe, though cautious monitoring of calcineurin inhibitor trough levels was advised due to potential drug-drug interactions.", "population_specificity": "Kidney transplant recipients with chronic hepatitis C virus infection.", "effective_dosage": "Fixed-dose sofosbuvir/ledipasvir combination for 12 or 24 weeks, with or without ribavirin.", "study_duration": "12 or 24 weeks.", "interactions": "Potential drug-drug interactions with calcineurin inhibitors.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:08.114187+00:00"}
{"study_id": 102632, "supplement_id": 863, "safety_score": "65", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the safety, tolerability, and efficacy of BI 456906, a GCGR/GLP-1R dual agonist, in reducing body weight and its effects on plasma alanine levels in Japanese men with overweight/obesity.", "results_summary": "BI 456906 reduced plasma alanine levels, indicating indirect target engagement at GCGRs and GLP-1Rs, and significantly decreased placebo-corrected body weight by up to 12.37% after 16 weeks. However, adverse events, including decreased appetite, led to withdrawals in 37% of participants receiving BI 456906.", "population_specificity": "Healthy Japanese men with a body mass index of 23 to 40 kg/m\u00b2.", "effective_dosage": "Maximum doses: 1.8 mg once weekly (DG 1), 4.8 mg once weekly (DG 2), and 2.4 mg twice weekly (DG 3).", "study_duration": "16 weeks.", "interactions": "Transient delayed gastric emptying was noted, as indicated by decreased paracetamol absorption in Week 1 for DGs 2 and 3.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:10.716267+00:00"}
{"study_id": 102635, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to describe hematological and biochemical parameters, including alanine transaminase levels, in children with cerebral palsy.", "results_summary": "The study noted alanine transaminase levels as part of biochemical parameters but did not specifically analyze its effects or outcomes. No significant findings related to alanine were reported.", "population_specificity": "Children diagnosed with cerebral palsy admitted to a pediatric department.", "effective_dosage": "Not available", "study_duration": "Four-year observational study", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:11.013282+00:00"}
{"study_id": 102634, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety and effectiveness of adjuvant UFT/LV chemotherapy in elderly patients (\u226580 years) with stage III colorectal cancer.", "results_summary": "The study found that 67.3% of patients completed the treatment, but 21 discontinued due to adverse events or refusal. Grade three or higher adverse events included neutropenia, liver enzyme elevation, oral mucositis, anemia, and diarrhea.", "population_specificity": "Patients aged \u226580 years with stage III colorectal cancer who underwent curative resection.", "effective_dosage": "UFT 300 mg/m\u00b2 and leucovorin (LV) dosage not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:12.283614+00:00"}
{"study_id": 102639, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to highlight the role of LC-MS/MS in identifying protein biomarkers, including Alanine transaminase, for early detection and monitoring of COVID-19 severity.", "results_summary": "The abstract mentions Alanine transaminase as a clinically significant protein biomarker in COVID-19, analyzed by LC-MS/MS, but does not provide specific results regarding its effects.", "population_specificity": "COVID-19 patients (specific demographics not detailed).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:15.033518+00:00"}
{"study_id": 102637, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to compare the effects of SGLT2 inhibitors and TZDs on liver enzymes (including alanine aminotransferase, ALT), steatosis, and fibrosis in patients with NAFLD, with or without T2DM.", "results_summary": "Both SGLT2 inhibitors and TZDs showed equivalent, non-significant improvements in ALT, AST, GGT, hepatic fibrosis, and other metabolic markers. SGLT2 inhibitors significantly reduced visceral fat area and body weight compared to TZDs.", "population_specificity": "311 patients with NAFLD, with or without type 2 diabetes mellitus (T2DM).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:15.034992+00:00"}
{"study_id": 102636, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to compare the incidence of statin-associated muscle symptoms (SAMS) in elderly patients with ASCVD receiving intensive statin monotherapy versus combination therapy, including monitoring alanine transaminase levels as a secondary endpoint.", "results_summary": "The abstract does not report specific results regarding alanine transaminase levels or Alanine's effects, as the study primarily focused on SAMS and LDL-cholesterol outcomes.", "population_specificity": "Patients aged 70 years or older with established atherosclerotic cardiovascular disease (ASCVD).", "effective_dosage": "Not specified for Alanine (study used rosuvastatin 20 mg or rosuvastatin/ezetimibe 5/10 mg).", "study_duration": "6 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:15.047089+00:00"}
{"study_id": 102638, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the prognostic impact of serum biomarkers, including the De Ritis ratio (aspartate aminotransferase/alanine transaminase), in patients with resected atypical meningiomas.", "results_summary": "The study found that a postoperative De Ritis ratio >2 was associated with higher progression/recurrence rates in atypical meningioma patients, particularly in those not treated with adjuvant radiation therapy. Other serum markers like platelet count and neutrophil-to-lymphocyte ratio also showed prognostic significance.", "population_specificity": "523 patients with resected intracranial atypical meningiomas from 5 Asian institutions.", "effective_dosage": "Not specified", "study_duration": "Not specified (serum data collected within 1 week post-surgery)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:15.825300+00:00"}
{"study_id": 102641, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety and efficacy of therapeutics, including brincidofovir, for treating mpox, with a focus on liver injury indicated by raised alanine aminotransferase (ALT) levels.", "results_summary": "The study found very low-certainty evidence suggesting brincidofovir may cause mild liver injury (raised ALT levels) in mpox patients, but no severe drug-induced liver injury was reported. Alanine itself was not directly studied for safety or efficacy.", "population_specificity": "Humans with mpox infection, including those at greater risk of severe disease.", "effective_dosage": "Not specified for alanine.", "study_duration": "Not specified for alanine.", "interactions": "None mentioned for alanine.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:19.520591+00:00"}
{"study_id": 102642, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to investigate the safety and efficacy of concurrent pembrolizumab with AVD (doxorubicin, vinblastine, and dacarbazine) in untreated classic Hodgkin lymphoma, including monitoring for alanine aminotransferase elevation as an adverse event.", "results_summary": "The study found that grade 3 or 4 immune-related adverse events, including alanine aminotransferase elevation, occurred in 3 patients. Six patients missed pembrolizumab doses due to adverse events, primarily transaminitis.", "population_specificity": "30 patients with untreated classic Hodgkin lymphoma.", "effective_dosage": "Not specified for alanine aminotransferase elevation.", "study_duration": "Median follow-up of 2.1 years.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:20.238559+00:00"}
{"study_id": 102643, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to assess the impact of lifestyle optimization (including diet and exercise) on liver regeneration and outcomes in live liver donors, with a focus on markers like Alanine transaminase.", "results_summary": "The intervention group showed significantly lower postoperative peak Alanine transaminase levels (P=0.025), indicating improved liver function, alongside better liver regeneration and reduced early graft dysfunction in recipients.", "population_specificity": "Live liver donors (LLDs) with no or minimal steatosis.", "effective_dosage": "Not specified (customized low-calorie diet matching basal requirements).", "study_duration": "2 weeks before surgery.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:22.032731+00:00"}
{"study_id": 102644, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 75, "study_goal": "The researchers aimed to determine the efficacy of empagliflozin versus placebo in treating non-alcoholic fatty liver disease, including its effects on alanine aminotransferase (ALT) levels.", "results_summary": "The meta-analysis found that empagliflozin treatment showed no significant improvement in ALT levels, hepatic steatosis, liver stiffness, or other metabolic markers compared to placebo, suggesting it may not be effective for non-alcoholic fatty liver disease.", "population_specificity": "Patients with non-alcoholic fatty liver disease (212 participants across three RCTs).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:23.313285+00:00"}
{"study_id": 102647, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the clinical efficacy of supplementing qi dispelling wind and activating blood circulation methods, including their impact on alanine transaminase levels, in treating IgA nephropathy (IgAN).", "results_summary": "The study found that the treatment method significantly improved renal function and reduced 24-hour urinary protein levels without affecting normal alanine transaminase levels, hemoglobin, or serum albumin.", "population_specificity": "Patients with IgA nephropathy (IgAN).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:23.616751+00:00"}
{"study_id": 102646, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the efficacy and safety of PD1/PDL1 inhibitors combined with radiotherapy and anti-angiogenic agents, including the impact on alanine aminotransferase levels as an adverse event.", "results_summary": "The study found that increased alanine aminotransferase (22%) was a common adverse event of the triple therapy, but the overall safety profile was deemed tolerable. The efficacy of the combination therapy was positive compared to monotherapy or dual therapy.", "population_specificity": "Patients with solid cancers", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:23.733382+00:00"}
{"study_id": 102645, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the effectiveness of curcumin supplementation, alone or combined with non-pharmacological therapies, in improving metabolic and liver health markers, including alanine aminotransferase (ALT), in individuals with MAFLD.", "results_summary": "The study found that curcumin supplementation, with or without lifestyle changes, led to statistically significant improvements in ALT, AST, FBI, HOMA-IR, TG, TC, and WC, suggesting potential benefits for MAFLD management. However, the authors noted the need for more rigorous studies to confirm these findings.", "population_specificity": "Individuals with metabolic (dysfunction)-associated fatty liver disease (MAFLD), often accompanied by obesity, diabetes, pre-diabetes, or hypertension.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:24.158239+00:00"}
{"study_id": 102640, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to compare peri-operative and long-term survival outcomes between minimally invasive liver resection (MILR) and open liver resection (OLR) in patients with hepatocellular carcinoma (HCC), not specifically to evaluate Alanine.", "results_summary": "The study found that MILR resulted in less blood loss, fewer blood transfusions, lower post-operative complications, and shorter hospital stays compared to OLR, with comparable long-term survival outcomes. Alanine transferase (ALT) levels were among the matched factors but were not a primary focus of the results.", "population_specificity": "Patients with hepatocellular carcinoma (HCC) who underwent liver resection.", "effective_dosage": "Not available", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:27.441847+00:00"}
{"study_id": 102648, "supplement_id": 863, "safety_score": "85", "efficacy_score": null, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the safety, tolerability, and effect of fezolinetant on endometrial health over 52 weeks, including assessing treatment-emergent adverse events and endometrial health.", "results_summary": "The study found that fezolinetant was generally safe and well-tolerated, with similar rates of adverse events across placebo and treatment groups. Endometrial hyperplasia and malignancy rates were low, and liver enzyme elevations were rare, with no severe drug-induced liver injury reported.", "population_specificity": "Postmenopausal women seeking treatment for vasomotor symptoms associated with menopause.", "effective_dosage": "30 mg and 45 mg once daily.", "study_duration": "52 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:27.921962+00:00"}
{"study_id": 102650, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to investigate the survival benefits of combining sintilimab, apatinib, and chemotherapy in patients with previously treated advanced gastric or gastroesophageal junction (GEJ) cancer, not specifically focusing on Alanine.", "results_summary": "The study did not specifically evaluate Alanine's effects but reported elevated alanine aminotransferase as one of the grade 3-4 adverse events in the context of the combination therapy.", "population_specificity": "Patients with previously treated advanced gastric or GEJ adenocarcinoma.", "effective_dosage": "Not specified for Alanine.", "study_duration": "Until disease progression, intolerable toxicity, or withdrawal of consent.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:30.005818+00:00"}
{"study_id": 102649, "supplement_id": 863, "safety_score": "70", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety, tolerability, and management of treatment-related adverse events (TRAEs) associated with adagrasib, including hepatic toxicities like increased alanine aminotransferase/aspartate aminotransferase.", "results_summary": "The study found that adagrasib-related TRAEs, including hepatic toxicities (elevated alanine aminotransferase/aspartate aminotransferase), were generally mild to moderate, manageable with interventions, and resulted in low treatment discontinuation rates. Practical guidance for managing these TRAEs was provided to optimize patient outcomes.", "population_specificity": "Patients with KRASG12C-mutated solid tumors, including those with CNS metastases.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:30.428178+00:00"}
{"study_id": 102651, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the association between food restriction and liver enzyme levels, including alanine transferase (ALT), aspartate transferase (AST), and \u03b3-glutamyl transferase (GGT).", "results_summary": "The meta-analysis found that food restriction reduced ALT levels (SMD -0.36) and GGT levels (SMD -0.23), with AST levels decreasing in medium-term interventions (SMD -0.48). The study concluded that dietary restriction improves adult liver enzyme levels.", "population_specificity": "Adults (1982 participants across 17 trials)", "effective_dosage": "Not specified", "study_duration": "Varied (medium-term defined as 5 weeks to 6 months)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:31.449527+00:00"}
{"study_id": 102652, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study aimed to assess the efficacy and safety of tafolecimab, a PCSK9 monoclonal antibody, in Chinese patients with heterozygous familial hypercholesterolemia (HeFH), not Alanine.", "results_summary": "The study found that tafolecimab significantly reduced LDL-C levels and other lipid parameters, with a favorable safety profile, but did not evaluate Alanine.", "population_specificity": "Chinese patients with heterozygous familial hypercholesterolemia (HeFH)", "effective_dosage": "Tafolecimab 150 mg every 2 weeks or 450 mg every 4 weeks", "study_duration": "12-week double-blind treatment followed by 12-week open-label treatment", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:31.883863+00:00"}
{"study_id": 102653, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced NSCLC patients.", "results_summary": "Iruplinalkib demonstrated favorable efficacy with an IRC-assessed ORR of 69.9% and DCR of 96.6%, along with manageable safety profiles, though common TRAEs included increased alanine aminotransferase (37.0%).", "population_specificity": "ALK-positive crizotinib-resistant advanced NSCLC patients aged \u226518 years with ECOG performance status 0-2.", "effective_dosage": "180 mg orally once daily (with a 7-day lead-in phase at 60 mg orally once daily).", "study_duration": "Median follow-up time was 18.2 months.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:32.597729+00:00"}
{"study_id": 102654, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate the effects of liraglutide on type 2 diabetes mellitus (T2DM) with nonalcoholic fatty liver disease (NAFLD), including its impact on alanine aminotransferase levels.", "results_summary": "The study found that alanine aminotransferase levels were lower in the experimental group compared to the control group in 10 out of the 16 studies analyzed, indicating a potential benefit of liraglutide. No significant difference in aspartate transaminase changes was observed between the two groups.", "population_specificity": "Patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:33.445213+00:00"}
{"study_id": 102655, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine the association between liver injury (including alanine aminotransferase levels) and the severity of COVID-19.", "results_summary": "The study found that hepatocellular injury, including elevated alanine aminotransferase levels, was associated with severe COVID-19, suggesting liver injury may serve as a prognostic biomarker for disease severity.", "population_specificity": "Patients diagnosed with COVID-19 (28,663 participants across 46 studies).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:34.482180+00:00"}
{"study_id": 102656, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the role of alanine as a conventional biomarker for mitochondrial disease diagnosis and follow-up, alongside newer biomarkers like FGF21 and GDF15.", "results_summary": "The study found that alanine, along with lactate and pyruvate, is a conventional biomarker for mitochondrial diseases but is outperformed in specificity and sensitivity by newer biomarkers like FGF21 and GDF15 for muscle-manifesting mitochondrial diseases.", "population_specificity": "Patients with mitochondrial diseases, particularly those with muscle-manifesting symptoms.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:35.842622+00:00"}
{"study_id": 102657, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to establish consensus guidelines for metabolic investigations, including the assessment of amino acids like Alanine, in diagnosing mitochondrial disorders.", "results_summary": "The study outlines diagnostic approaches for mitochondrial disorders, recommending the assessment of amino acids in blood and urine, but does not specifically report on Alanine's effects.", "population_specificity": "Patients with suspected mitochondrial disorders.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:37.048327+00:00"}
{"study_id": 102658, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the association between higher alanine aminotransferase levels and the risk of NAFLD in persons with HIV (PWH).", "results_summary": "Higher alanine aminotransferase levels were independently associated with increased NAFLD risk in PWH, but the study did not focus on alanine supplementation or direct effects.", "population_specificity": "Persons with HIV (PWH) in outpatient clinics across three US centers.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:37.474593+00:00"}
{"study_id": 102660, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine the effect of curcumin + piperine on cardiometabolic risk factors, hepatic steatosis, and fibrosis in NAFLD patients with moderate-to-high hepatic steatosis.", "results_summary": "Curcumin + piperine improved waist circumference, blood pressure, lipid profile, blood glucose, and liver enzymes, but did not significantly affect fibroscan measurements for hepatic fibrosis.", "population_specificity": "Patients diagnosed with moderate-to-high NAFLD by liver sonography.", "effective_dosage": "500 mg/day curcumin plus 5 mg/day piperine.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:39.869409+00:00"}
{"study_id": 102659, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the hepatotoxicity profile, spectrum, and safety ranking of immune checkpoint inhibitor drugs, including their effects on alanine aminotransferase levels.", "results_summary": "The study found that the combination of programmed death ligand 1 inhibitor, targeted therapy, and chemotherapy had the highest risk of increasing alanine aminotransferase levels. No significant difference in immune-related hepatotoxicity was found between PD-1 and CTLA-4 inhibitors for all-grade hepatotoxicity, but CTLA-4 inhibitors had a higher risk of severe hepatotoxicity.", "population_specificity": "Cancer patients treated with immune checkpoint inhibitors (n=164,782).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:41.005395+00:00"}
{"study_id": 102661, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effectiveness of metformin and pioglitazone combined with vitamin E on liver enzyme levels (including alanine aminotransferase) and sonography grade in non-alcoholic fatty liver disease patients.", "results_summary": "Metformin combined with vitamin E significantly reduced alanine aminotransferase levels and improved sonography grade, while pioglitazone with vitamin E showed no significant changes in liver enzymes.", "population_specificity": "68 patients diagnosed with non-alcoholic fatty liver disease.", "effective_dosage": "Vitamin E at 800 IU daily; metformin at 1000 mg daily; pioglitazone at 15 mg daily.", "study_duration": "6 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:41.087564+00:00"}
{"study_id": 102662, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to assess the real-world efficacy and safety of glecaprevir and pibrentasvir (G/P) treatment in Japanese adolescents with chronic HCV infection, including its effects on serum alanine aminotransferase levels.", "results_summary": "The study found that G/P treatment significantly decreased serum alanine aminotransferase levels and achieved a 96% sustained virologic response rate (SVR12) with mild adverse events and no serious effects on growth or maturation.", "population_specificity": "Japanese adolescents aged 12-17 years with chronic HCV infection.", "effective_dosage": "300 mg glecaprevir and 120 mg pibrentasvir once daily.", "study_duration": "8 or 12 weeks.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:42.425826+00:00"}
{"study_id": 102664, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to evaluate whether a new nutraceutical supplement composition, including Alanine, could improve metabolic and endocrine parameters related to obesity.", "results_summary": "The study found reductions in waist circumference, waist-to-height ratio, waist-to-hip ratio, and improvements in biomarkers like the AST/ALT ratio (a NAFLD indicator), cortisol, and TSH levels after supplementation.", "population_specificity": "Sedentary adults (women and men) with a BMI \u226434.9 kg/m\u00b2.", "effective_dosage": "Not specified", "study_duration": "180 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:43.907932+00:00"}
{"study_id": 102663, "supplement_id": 863, "safety_score": "85", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the safety, tolerability, pharmacokinetics, and relative bioavailability of AXA1665, a fixed-ratio amino acid composition containing Alanine, compared to a standard protein supplement.", "results_summary": "The study found a dose-dependent increase in plasma AUC for AXA1665, indicating effective absorption, but did not report specific efficacy outcomes for Alanine alone. The pharmacokinetics and bioavailability of constituent AAs were assessed, but clinical effects were not detailed.", "population_specificity": "Healthy subjects (N = 16)", "effective_dosage": "4.9 g, 9.8 g, 19.6 g, 29.4 g, and 39.2 g of AXA1665; 35 g protein supplement (single doses)", "study_duration": "Single-dose administration in a crossover design", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:44.578825+00:00"}
{"study_id": 102666, "supplement_id": 863, "safety_score": "70", "efficacy_score": 80, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety and efficacy of sotorasib, including its impact on alanine aminotransferase levels, compared to docetaxel in patients with advanced NSCLC and KRAS mutations.", "results_summary": "Sotorasib showed a statistically significant increase in progression-free survival compared to docetaxel, with a more favorable safety profile. Alanine aminotransferase increase was a common treatment-related adverse event (8% in the sotorasib group).", "population_specificity": "Patients aged \u226518 years with advanced NSCLC and KRAS mutations.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Median follow-up of 17.7 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:45.623148+00:00"}
{"study_id": 102667, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to assess the effect of a culturally tailored Patient Navigator-led Intervention on chronic hepatitis B monitoring and treatment adherence, including alanine aminotransferase (ALT) testing, among Asian Americans.", "results_summary": "The intervention group showed significantly higher rates of doctor visits and ALT testing compared to the control group at both 6-month and 12-month follow-ups, indicating improved adherence to monitoring and care. The culturally appropriate intervention had strong effects on follow-up care adherence among Asian American hepatitis B patients.", "population_specificity": "Asian Americans with chronic hepatitis B in the greater Philadelphia and New York City metropolitan areas.", "effective_dosage": "Not specified", "study_duration": "12 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:45.803690+00:00"}
{"study_id": 102669, "supplement_id": 863, "safety_score": "80", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to explore the mechanism of Spleen-strengthening and liver-draining formula (SLF) against NAFLD, particularly its effects on glucolipid metabolism and intestinal flora.", "results_summary": "SLF improved liver function, reduced liver fat content, and enhanced glucolipid metabolism in NAFLD patients. It also modulated intestinal flora diversity and species abundance.", "population_specificity": "Patients with non-alcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:48.590743+00:00"}
{"study_id": 102668, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to investigate the impact of TACE and HAIC on liver function, including alanine transaminase levels, in HCC patients post-resection.", "results_summary": "The study found that TACE significantly increased alanine transaminase levels short-term, while HAIC had a smaller impact. Long-term liver function was unaffected by either treatment.", "population_specificity": "138 hepatocellular carcinoma (HCC) patients post-resection.", "effective_dosage": "Not specified", "study_duration": "Short-term and long-term effects assessed (exact duration not specified).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:48.708643+00:00"}
{"study_id": 102671, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to review long-term and real-world data on the tolerability, safety, and efficacy of lasmiditan, ubrogepant, and rimegepant for acute migraine treatment, including potential effects on alanine transaminase levels.", "results_summary": "The study noted two cases of increased alanine transaminase levels possibly related to ubrogepant, but levels normalized despite continued use. No significant cardiovascular adverse events were linked to the medications.", "population_specificity": "Patients with chronic migraine, including those with comorbidities, cardiovascular diseases, and polypharmacy.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:51.187252+00:00"}
{"study_id": 102672, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers were reporting a case of brain abscess caused by Parvimonas micra infection, noting the presence of alanine in magnetic resonance spectroscopy.", "results_summary": "The study found a peak alanine concentration of 1.5 ppm in the brain abscess but did not evaluate alanine's therapeutic or adverse effects. The focus was on diagnosing and treating the abscess, not alanine's role.", "population_specificity": "A 47-year-old woman with a brain abscess.", "effective_dosage": "Not available", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:51.216386+00:00"}
{"study_id": 102673, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the efficacy and safety of ursodeoxycholic acid (UDCA) in children with cholestasis, including its effects on serum alanine aminotransferase levels.", "results_summary": "UDCA improved symptoms of cholestasis and reduced serum levels of alanine aminotransferase, total bilirubin, direct bilirubin, and total bile acid. Adverse drug reactions were primarily gastrointestinal, with no significant difference in incidence compared to placebo/blank control.", "population_specificity": "Children with cholestasis.", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:52.729711+00:00"}
{"study_id": 102674, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate whether alanine mediates the causal association between lower birthweight and non-alcoholic fatty liver disease (NAFLD).", "results_summary": "The study found that alanine partially mediates (10.01%) the effect of lower birthweight on NAFLD risk. Additionally, bidirectional Mendelian randomization suggested a unidirectional effect of alanine on insulin resistance.", "population_specificity": "Europeans (298,142 for birthweight GWAS; 8434 NAFLD cases and 770,180 controls for NAFLD GWAS)", "effective_dosage": "Not available", "study_duration": "Not applicable (Mendelian randomization study)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:54.748426+00:00"}
{"study_id": 102675, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study does not address Alanine; it focuses on the effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) for retreating East Asian HCV patients previously treated with NS5A inhibitor-containing DAAs.", "results_summary": "The study does not provide any results related to Alanine.", "population_specificity": "East Asian HCV patients who failed NS5A inhibitor-containing DAAs.", "effective_dosage": "Not mentioned (for Alanine).", "study_duration": "Not mentioned (for Alanine).", "interactions": "None mentioned (for Alanine).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:54.923623+00:00"}
